Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.

开始日期2025-12-01

申办/合作机构

Centre Hospitalier Universitaire de Nimes

TCTR20241218002

/ Not yet recruiting临床4期IIT

A Randomized Controlled Trial of colistin combined with sulbactam versus colistin combined with sulbactam and high dose tigecycline in treatment of carbapenems resistant Acinetobacter baumannii (CRAB) pneumonia

开始日期2024-12-25

申办/合作机构

Phramongkutklao College of Medicine

NCT06893835

/ Active, not recruiting临床4期IIT

Comparative Study of Clinical Outcomes and Safety Between Colistin and Tigecycline for Multi-Drug Resistant Gram Negative Bacteria

Objective from this study to compare the clinical outcomes and safety between colistin and tigecycline for multi-drug resistant gram negative bacteria.

开始日期2024-12-01

申办/合作机构

Beni-Suef University

100 项与替加环素相关的临床结果

登录后查看更多信息

100 项与替加环素相关的转化医学

登录后查看更多信息

100 项与替加环素相关的专利（医药）

登录后查看更多信息

6,786

项与替加环素相关的文献（医药）

2026-02-01·DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

In vitro activity of essential antimicrobial agents, including ceftazidime/avibactam, imipenem/relebactam, and cefiderocol, against carbapenem-resistant Gram-negative bacteria primarily harboring the IMP-type carbapenemase gene in the Kinki region of Japan

Article

作者: Komatsu, Masaru ; Kuchibiro, Tomokazu ; Sawa, Kana ; Niki, Makoto ; Nakamura, Akihiro ; Yamasaki, Katsutoshi ; Nakamura, Tatsuya

OBJECTIVE:

In cases of infections caused by multidrug-resistant Gram-negative bacilli (MRGNB), the efficacy of various antimicrobial agents may be limited due to antimicrobial resistance. This study evaluated the antimicrobial activity of various antimicrobials, principally novel beta-lactam beta-lactamase inhibitor combinations, against MRGNB prevalent in the Kinki region of Japan.

METHODS:

A total of 207 strains were utilized in the study, encompassing 108 carbapenemase-producing Enterobacterales (CPE) strains, 9 carbapenemase-non-producing carbapenem-resistant Enterobacterales (non-CP-CRE) strains, 73 carbapenem-resistant Pseudomonas aeruginosa (CRPA) strains, and 17 carbapenem-resistant Acinetobacter spp. (CRA) strains. These strains were obtained from the Study of Bacterial Resistance in the Kinki Region of Japan. Antimicrobial susceptibility testing was assessed via broth microdilution, with MICs determined according to the Clinical and Laboratory Standards Institute standards.

RESULTS:

The MIC₅₀/MIC₉₀ values (in μg/mL) for each antimicrobial agent were determined for the CPE, non-CP-CRE, CRPA, and CRA strains. The following agents demonstrated activity: ceftazidime/avibactam (CAZ/AVI) (16/>16, 2/8, 8/16, 16/>16), piperacillin/tazobactam (8/>64, >64/>64, 64/>64, 8/>64), ceftolozane/tazobactam (CTLZ/TAZ) (>32/>32, 16/>32, 8/>32, >32/>32), imipenem/relebactam (IPM/REL) (0.25/4, 1/2, 8/>8, >8/>8), tigecycline (≤0.5/2, 1/8, >8/>8, ≤0.5/1), colistin (1/2, 1/8, 1/1, 1/2), and cefiderocol (0.25/2, 1/16, 1/8, 0.5/32).

CONCLUSION:

The MIC distributions for colistin, tigecycline, and cefiderocol were narrow across resistant strains, indicating consistent activity. Furthermore, the MIC distributions of CAZ/AVI and IPM/REL exhibited a narrow range of concentrations against non-CP-CRE and non-CP-CRPA, respectively. In contrast, CTLZ/TAZ exhibited a similarly narrow distribution against non-CP-CRPA. These findings suggest that these antimicrobials effectively treat infections caused by MRGNB.

2026-01-01·VETERINARY MICROBIOLOGY

Mechanism of horizontal transmission of tet(A)TIG multicopy structures in Escherichia coli of chicken origin

Article

作者: Xu, Chunyan ; Li, Dexi ; Shan, Xinxin ; Schwarz, Stefan ; Shang, Yanhong ; Yu, Runhao ; Du, Xiang-Dang ; Zou, Chenhui

Tigecycline is a vital antimicrobial to treat bacterial infection. Our previous studies have demonstrated that a variant of the tet(A) gene, tet(A)_TIG, can enhance Escherichia coli resistance to tigecycline through tandem amplification. However, the mechanism of tet(A) multicopy structure transfer remains unclear. In this study, we report the mechanism of tet(A)_TIG multicopy structure transfer with the assistance of plasmid recombination. S1-PFGE shows that the transconjugant 573_16xJ53-TC1 (hereinafter referred to as the "TC1") carries two plasmids. Interestingly, the sizes of these two plasmids do not match any plasmids in donor strain E. coli 573_16. Whole genome sequencing showed that TC1 carries only one plasmid, named p573_16xJ53-TC1 (hereinafter referred to as the "pTC1"). Sequence alignment indicates that the tet(A)_TIG multicopy structure was transferred from the donor strain to the recipient strain via plasmid p573_16-3, rather than its original p573_16-2. Genetic environment analysis indicated that the cross-plasmid transfer of the tet(A)_TIG gene was mediated by the unconventional circularizable structure (UCS) formed by homologous recombination of its upstream and downstream ΔTnAs1. Conjugation experiments indicate that the hybrid plasmid pTC1 still retains the ability for horizontal transfer. The tet(A)_TIG gene can cause cross-resistance to tetracycline and tigecycline, and its horizontal spread through different plasmids indicates a complex mode of transmission.

2026-01-01·DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Molecular analysis and ceftazidime–avibactam susceptibilities of carbapenem-resistant Klebsiella pneumoniae: Seven year experience from blood cultures of liver transplant recipients in a university hospital

Article

作者: Otlu, Baris ; Karabulut, Ertugrul ; Bayindir, Yasar ; Tanriverdi, Elif Seren ; Yilmaz, Sezai ; Duman, Yucel ; Yakupogullari, Yusuf ; Altunisik Toplu, Sibel

BACKGROUND:

Carbapenem-resistant Klebsiella pneumoniae (CRKP) infection is a major cause of mortality in liver transplantation (LT) recipients.

METHODS:

We aimed to elucidate the molecular mechanisms of carbapenem resistance among CRKP strains and determine ceftazidime-avibactam (CZA) in vitro susceptibility in high-risk patient populations, such as LT recipients.

RESULTS:

Of the 127 LT recipients between January 2016 and 2022, no statistically significant difference was found in the in vitro sensitivity of amikacin, gentamicin, ciprofloxacin, levofloxacin, imipenem, meropenem, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, tigecycline, and colistin in patients with CRKP sepsis who survived and died at 30 days, except for amikacin and meropenem, which was statistically significant at 90 days (p ≤ 0.05). Of the isolates, 120 (94.4 %) were positive for the modified carbapenem inactivation test. When the carbapenemase genes of 127 CRKP isolates were analyzed, the most common carbapenemase gene was OXA-48 (59.1 %). The presence of OXA-48, OXA-48 + NDM, NDM, IMP, and VIM genes in CRKP isolates showed a statistically significant difference with the CZA susceptibility result (p ˂ 0.05).

CONCLUSIONS:

The presence of the OXA-48 resistance gene in CRKP isolates was closely associated with in vitro susceptibility to CZA, regardless of the diversity of the patient population.

134

项与替加环素相关的新闻（医药）

2025-12-03

·北京医学感染与传染研究

抗菌化疗杂志 80卷 7-12期、增刊2、4期（2025年12月3日更新）

Journal of Antimicrobial Chemotherapy Volume 80, Issue 7抗菌化疗杂志 80卷 7期 https://academic.oup.com/jac/issue REVIEWS（综述） 1 The role of antimicrobial prophylaxis in brachytherapy for prostate, breast and gynaecological cancer: a narrative review 抗生素预防用药在前列腺、乳腺及妇科癌症近距离治疗中的作用：叙述性综述 Konstantinos Alexakis and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1753–1771, 2 To be or not to be: the non-antimicrobial properties of common antimicrobials 生存还是毁灭：常见抗菌药物的非抗菌特性 Shivakumar Narayanan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1772–1783, SYSTEMATIC REVIEWS（系统综述） 3 Antibiotic-induced Bartter-like syndrome: a systematic review 抗生素诱发的巴特综合征样表现：系统综述 Megha Priyadarshi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1784–1791, 4 Liposomal amphotericin B prophylaxis in paediatrics: a systematic review 两性霉素B脂质体预防性用药在儿科中的应用：系统综述 Emma V Thorley and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1792–1802, ORIGINAL RESEARCH（论著） 5 Antibiotic use attributable to RSV infections during infancy—an international prospective birth cohort study 婴儿期呼吸道合胞病毒感染所致抗生素使用情况——一项国际前瞻性出生队列研究 Sarah F Hak and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1803–1812, 6 Plasmodium falciparum isolates: ex vivo drug response 恶性疟原虫分离株：体外药物反应 Edem Adika and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1813–1822, 7 Impact of hypoalbuminemia on patients receiving ertapenem combination therapy for methicillin-susceptible Staphylococcus aureus bacteraemia 低白蛋白血症对接受厄他培南联合疗法治疗甲氧西林敏感金黄色葡萄球菌菌血症患者的影响 Sunish Shah and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1823–1827, 8 Exploring community pharmacy professionals and general practitioners’ views on primary care communication and pathways to access antibiotics in England 探究英国社区药房专业人员和全科医生对初级保健沟通及获取抗生素途径的看法 Ming Xuan Lee and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1828–1836, 9 Decline of antimicrobial resistance in Pseudomonas aeruginosa bacteraemia following the COVID-19 pandemic: a longitudinal observational study 新冠疫情后铜绿假单胞菌菌血症抗菌药物耐药性的下降：一项纵向观察研究 Yulia Butscheid and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1837–1848, 10 Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy 意大利HIV感染者（HIV-RNA不可检测）特定合并症与抗逆转录病毒药物转换概率：一项回顾性分析 Alessandro Cozzi-Lepri and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1849–1859, 11 Model-based translation of the PKPD-relationship for linezolid and vancomycin on methicillin-resistant Staphylococcus aureus: from in vitro time–kill experiments to a mouse pneumonia model 基于模型转化利奈唑胺和万古霉素对甲氧西林耐药金黄色葡萄球菌的药代动力学-药效学关系：从体外时间杀菌实验到小鼠肺炎模型 Diego Vera-Yunca and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1860–1868, 12 Inner-mitochondrial membrane protein PfMPV17 is linked to P. falciparum in vitro resistance to the indoloquinolizidine alkaloid alstonine 线粒体内膜蛋白PfMPV17与恶性疟原虫对吲哚醌啉生物碱阿尔斯通宁的体外耐药性相关 J R Macdonald and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1869–1877, 13 Efficacy and tolerability of the combination of minocycline and metronidazole for macrolide-resistant Mycoplasma genitalium 米诺环素与甲硝唑联合治疗大环内酯类耐药生殖支原体感染的疗效和耐受性 Kay Htaik and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1878–1884, 14 Early use of the novel antifungal rezafungin: a case series and literature review 新型抗真菌药物瑞扎芬净的早期使用：病例系列报道及文献综述 H C Davidson and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1885–1892, 15 Optimal dosing of amoxicillin in obese and post-gastric bypass patients using a population pharmacokinetics-pharmacodynamics model approach 基于群体药代动力学-药效学模型方法确定阿莫西林在肥胖和胃旁路术后患者中的最佳剂量 Gisela Myrian de Lima Leite Dalla Rosa and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1893–1901, 16 Decreasing antimicrobial resistance in representative UK livestock species was associated with reduced total sales of antimicrobials in the last decade 过去十年，英国代表性家畜物种抗菌药物耐药性下降与抗菌药物总销量减少相关 Aliya El Nagar and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1902–1906, 17 An improved multiplex RT–quantitative PCR assay can reveal sex-specific activity of transmission-blocking drugs on ex vivo gametocytes from Plasmodium falciparum asymptomatic infections 一种改进的多重逆转录定量聚合酶链反应检测法可揭示性特异性抗疟疾传播阻断药物对恶性疟原虫无症状感染体外配子体活性的影响 Mariagrazia Ciardo and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1907–1914, 18 Population pharmacokinetics and thrombocytopenia risk assessment of linezolid in liver transplant recipients 利奈唑胺在肝移植受者中的群体药代动力学及血小板减少症风险评估 Xiaoping Shi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1915–1925, 19 Rapid susceptibility testing on urine for antimicrobial stewardship in general practice 全科实践中的尿液快速药敏试验助力抗菌药物管理 Patrick D J Sturm and Tanja Schülin Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1926–1932, 20 Efficacy of linezolid in monotherapy q12h versus q8h versus combined with daptomycin in the treatment of experimental endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus strains 利奈唑胺单药治疗每12小时一次与每8小时一次，以及与达托霉素联合治疗甲氧西林耐药和糖肽中介金黄色葡萄球菌菌株所致实验性心内膜炎的疗效 María-Alexandra Cañas and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1933–1941, 21 In vitro activity of NOSO-502, a novel-action antimicrobial, against clinical strains of Enterobacterales including MDR strains 新型作用机制抗菌药物NOSO-502对包括多重耐药菌株在内的肠杆菌科临床菌株的体外活性 Marie L G Attwood and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1942–1946, 22 Antibacterial activity of propylene glycol against Staphylococcus aureus and Staphylococcus epidermidis in neutral and mild acidic conditions 中性及弱酸性条件下，丙二醇对金黄色葡萄球菌和表皮葡萄球菌的抗菌活性 Nadiia Mosiichuk and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1947–1950, 23 Molecular characteristics of chromosome-mediated colistin resistance in foodborne Salmonella isolates in China 中国食源性沙门氏菌分离株染色体介导的多粘菌素耐药性的分子特征 Zeqiang Zhan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1951–1963, 24 High azole non-wild type rates and nosocomial microsatellite typing aggregation of Wickerhamomyces anomalus in China according to a 12-year multicenter surveillance study 根据一项为期12年的多中心监测研究，中国异常威克汉姆酵母属唑类非野生型率高且医院内微卫星分型聚集 Zhengyu Luo and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1964–1971, 25 Repurposing antimalarials: pyrimethamine exhibits superior in vitro activity to metronidazole against Gardnerella while sparing Lactobacillus 抗疟药物再利用：乙胺嘧啶对加德纳菌的体外活性优于甲硝唑，且对乳酸杆菌无影响 Aliona S Rosca and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1972–1979, 26 Clinical characteristics and risk factors of tigecycline-induced acute pancreatitis in kidney transplant recipients: a retrospective study 肾移植受者替加环素诱发急性胰腺炎的临床特征及危险因素：一项回顾性研究 Lijuan Feng and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1980–1987, 27 Genomic characteristics of the multiresistant Acinetobacter baumannii global clone 1 reference strain A297/RUH875 多重耐药鲍曼不动杆菌全球克隆1型参考菌株A297/RUH875的基因组特征 Jonathan Koong and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1988–1992, 28 Comparison of a modified broth microdilution Sensititre™ SLOMYCOI assay with the CLSI-recommended agar disk elution method for antimicrobial susceptibility testing of Mycobacterium haemophilum 改良肉汤微量稀释Sensititre™ SLOMYCOI检测法与CLSI推荐的琼脂稀释法对嗜血杆菌属抗菌药物敏感性检测的比较 Doris Hillemann and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1993–1996, 29 Reversal of phenotypic resistance in multi-drug resistant carbapenemase-producing K. pneumoniae clinical isolates due to in vitro synergistic interactions between bacteriophages and antibiotics at clinically achievable concentrations 由于细菌噬菌体和抗生素在临床可达到浓度下的体外协同作用，多重耐药碳青霉烯酶产生肺炎克雷伯菌临床分离株的表型耐药性发生逆转 Paschalis Paranos and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1997–2006, 30 Antibiotic resistance and population structure of Staphylococcus epidermidis from prosthetic joint infections in Sweden and France 瑞典和法国假体关节感染表皮葡萄球菌的抗生素耐药性和群体结构 Sofie M Edslev and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2007–2015, 31 Lines on the line: evaluating the impact of antibiotic lock therapy versus catheter removal in the management of central vascular catheter infections 抗生素锁疗法与导管拔除术治疗中心血管导管感染的影响评估 Nischal Ranganath and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2016–2024, 32 Real-time FT-IR typing of Klebsiella pneumoniae: a flexible and rapid approach for outbreak detection and infection control 肺炎克雷伯菌实时傅里叶变换红外分型：一种灵活快速的暴发检测和感染控制方法 Ana Beatriz Gonçalves and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2025–2031, 33 Antibiotic stress affects the secretion and physicochemical features of extracellular vesicles produced by Helicobacter pylori 抗生素压力影响幽门螺杆菌产生的细胞外囊泡的分泌和物理化学特性 Paweł Krzyżek and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2032–2043, 34 A novel azithromycin resistance mutation in Mycoplasma genitalium induced in vitro 生殖支原体体外诱导产生的新型阿奇霉素耐药突变 Teck-Phui Chua and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2044–2050, RESEARCH LETTERS（研究信函） 35 Posaconazole dosing of enteral formulations in infants and young children to achieve therapeutic concentrations 婴儿和幼儿肠内制剂泊沙康唑的给药剂量以达到治疗浓度 Jeffrey Harrington and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2051–2053, 36 Antimony used as rescue therapy in a kidney transplant recipient unresponsive to liposomal amphotericin B for chronic visceral leishmaniasis 两性霉素B脂质体治疗慢性内脏利什曼病无效的肾移植受者中使用锑剂作为挽救疗法 Natacha Mrozek and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2053–2056, 37 Is cefazolin an option for treatment of staphylococcal endogenous endophthalmitis? 头孢唑林是否可用于治疗葡萄球菌性内源性眼内炎？ Alexandra Morin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2057–2058, LETTER TO THE EDITOR（致编辑的信） 38 Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre—a counterpoint 单用替考拉宁治疗肠球菌感染性心内膜炎：一家转诊中心的回顾性和比较研究——反驳观点 Miguel Villamarín and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2059–2060, Journal of Antimicrobial Chemotherapy Volume 80, Issue 8 抗菌化疗杂志 80卷 8期 https://academic.oup.com/jac/issue Review(综述) 1 World Health Organisation’s Bacterial Pathogen Priority List (BPPL) 2017 and BPPL 2024 to combat global antimicrobial resistance crisis: ‘challenges and opportunities’ 世界卫生组织2017年和2024年用以应对全球抗菌药物耐药性危机的细菌病原体优先名单（BPPL）：“挑战与机遇” Vazhayil Hari Krishnaprasad and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2061–2069 Original Research(论著) 2 Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5years of surveillance prior to approval for clinical use (2019–2023) 氨曲南/阿维巴坦对欧洲医疗中心肠杆菌科细菌的活性：临床批准前5年（2019-2023年）监测总结 Helio S Sader and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2070–2079 3 High feasibility of salivary therapeutic drug monitoring in linezolid, but lower feasibility in tedizolid: a single-dose study in healthy subjects and a monocentric prospective exploratory study in patients who received linezolid 利奈唑胺唾液治疗药物监测可行性高，但替地唑胺可行性较低：一项健康受试者单剂量研究和一项接受利奈唑胺患者单中心前瞻性探索性研究 Hitoshi Kawasuji and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2080–2091 4 Establishment and validation of downsized hollow-fibre infection model and pharmacokinetics/pharmacodynamics analysis of VAN on Enterococcus faecium 缩小版中空纤维感染模型的建立与验证及万古霉素对粪肠球菌的药代动力学/药效学分析 Yukitaka Hayashi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2092–2099 5 Four-month clofazimine regimen for susceptible pulmonary TB: a randomized clinical trial 为期4个月的氯法齐明方案治疗敏感型肺结核：一项随机临床试验 Nusrat Shafiq and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2100–2108 6 An ex vivo model to determine transmembrane clearance of antimicrobials during continuous renal replacement therapy 用于确定连续性肾脏替代治疗期间抗菌药物跨膜清除率的体外模型 Cole McGrath and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2109–2116 7 Optimization and improvement of the disc diffusion method for mucoid Pseudomonas aeruginosa 黏液型铜绿假单胞菌纸片扩散法的优化与改进 Aixin Wang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2117–2125 8 HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: a national laboratory-based survey using remnant viral load samples, 2022 乌干达接受基于多替拉韦抗逆转录病毒方案的HIV感染者中HIV-1耐药性情况：2022年一项基于国家实验室使用剩余病毒载量样本的调查 Christine Watera and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2126–2134 9 Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women 与固定剂量相比，基于体重给药的CAP256V2LS（一种用于女性HIV预防的广谱中和抗体）群体药代动力学研究 Sharana Mahomed and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2135–2144 10 Gut microbiota and weight gain in people with HIV on integrase inhibitors: a five-year longitudinal study 接受整合酶抑制剂治疗的HIV感染者肠道微生物群与体重增加情况：一项为期五年的纵向研究 Javier García-Abellán and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2145–2157 11 Development of a ribavirin dosing regimen in transplant recipients with chronic hepatitis E virus infection: a population pharmacokinetic and -dynamic model 慢性戊型肝炎病毒感染移植受者利巴韦林给药方案的开发：一项群体药代动力学和药效学模型研究 Midas B Mulder and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2158–2168 12 Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort 长效卡博特韦/利匹韦林在病毒受抑制的HIV感染者中的治疗中断有效性和预测因素：来自Icona队列的现实数据 Roberta Gagliardini and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2169–2178 13 Five-days-on-two-days-off (FOTO) versus daily bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV: a pilot randomized clinical trial 病毒受抑制的HIV感染者中，5天用药2天停药（FOTO）方案与每日比克替拉韦/恩曲他滨/丙酚替诺福韦方案的对比：一项初步随机临床试验 Hsin-Yun Sun and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2179–2186 14 Reliability of disc diffusion testing and molecular epidemiology of penicillin-susceptible Staphylococcus aureus bacteraemia 青霉素敏感金黄色葡萄球菌菌血症的纸片扩散试验可靠性和分子流行病学研究 Pernilla Kihlberg and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2187–2193 15 Outcomes of ceftriaxone 2g versus 1g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study 住院肺炎患者每日头孢曲松2克与1克疗效对比：一项全国性回顾性队列研究 Jumpei Taniguchi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2194–2202 16 Oleanolic acid derivative bardoxolone combats multidrug-resistant Staphylococcus aureus by destroying cell membrane and pyruvate metabolism pathway 齐墩果酸衍生物巴多昔隆通过破坏细胞膜和丙酮酸代谢途径对抗多重耐药金黄色葡萄球菌 Yun-Dan Zheng and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2203–2213 17 Evaluation of amoxicillin and benzylpenicillin therapy in early-onset neonatal sepsis: a pharmacometric external validation and simulation study 阿莫西林和苄青霉素治疗早期新生儿败血症的评估：一项药效计量学外部验证和模拟研究 Tom C Zwart and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2214–2225 18 48Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial HIV感染者换用多替拉韦加拉米夫定治疗48周身体成分变化：DOLAM随机临床试验的计划子分析 Elisa de Lazzari and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2226–2233 19 The impact of inter-infection time on antimicrobial resistance profiles in women with multiple urinary tract infections over time 多次尿路感染女性患者感染间隔时间对抗菌药物耐药性特征的影响 Trenton Honda and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2234–2240 20 Development and evaluation of a novel rapid immunochromatographic assay for the detection of DHA-producing Enterobacterales 一种检测产DHA肠杆菌科细菌的新型快速免疫层析法的开发与评估 Christian Moguet and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2241–2246 21 Enterococcus faecium bacteraemia: a multicentre observational study focused on risk factors for clinical and microbiological outcomes 粪肠球菌菌血症：一项关注临床和微生物学结局风险因素的多中心观察性研究 Matteo Rinaldi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2247–2256 22 Indolocarbazoles as host-directed therapeutics against intracellular infections by methicillin-resistant Staphylococcus aureus 靛红咔唑类化合物作为宿主导向疗法对抗甲氧西林耐药金黄色葡萄球菌细胞内感染 Robin H G A van den Biggelaar and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2257–2268 23 Clinical validation of antimicrobial dosing regimens for continuous renal replacement therapy based on an ex vivo dosing algorithm 基于体外给药算法的连续性肾脏替代治疗抗菌药物给药方案的临床验证 Christina Koenig and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2269–2279 24 Novel integrative and conjugative elements carrying cfr(B) and cfr(C) linezolid resistance genes in Clostridioides difficile isolates from calves, Italy 意大利牛犊艰难梭菌分离株中携带cfr(B)和cfr(C)利奈唑胺耐药基因的新型整合性和接合性元件 Andrea Brenciani and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2280–2284 25 Characterization of Carbapenemase-producing Enterobacterales isolated from patients returning from Sub-Saharan Africa, France, 2015–2022 2015-2022年从撒哈拉以南非洲返回的法国患者中分离出的产碳青霉烯酶肠杆菌科细菌的特征 Corentin Poignon and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2285–2294 26 Penicillin-susceptible ST398 with strong biofilm-forming ability poses a significant threat to osteoarticular infections 具有强生物膜形成能力的青霉素敏感ST398型对骨关节感染构成重大威胁 Ye Jin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2295–2304 27 Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB 贝达喹啉、德拉马尼和莫西沙星与不同剂量苏特唑利或德帕唑利联合用药治疗药物敏感型肺结核的心脏安全性 Simon E Koele and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2305–2313 28 Comparison of ceftolozane/tazobactam and meropenem in treating bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacterales: a single-centre, retrospective, real-world study 头孢托唑坦/他唑巴坦与美罗培南治疗产超广谱β-内酰胺酶肠杆菌科细菌所致血流感染的对比：一项单中心回顾性现实研究 Dimitrios Basoulis and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2314–2322 Research Letters(研究信件) 29 Dalbavancin as chronic suppressive therapy in a patient undergoing monthly apheresis: a case report with therapeutic drug monitoring 达巴万星作为每月进行血浆置换术患者的长期抑制治疗：一项带治疗药物监测的病例报告 Carlo Pallotto and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2323–2324 30 A novel methicillin-resistant Staphylococcus aureus lineage (ST4174) with an uncharacterized SCCmec variant identified in Korean pigs 韩国猪体内发现的一种带有未表征SCCmec变体的新型甲氧西林耐药金黄色葡萄球菌谱系（ST4174） Hyeonwoo Cho and Kun Taek Park Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2325–2326 31 Time fixes everything, but not always: 10years of persistent PI mutations in the absence of pharmacological pressure—a case report 时间能治愈一切，但并非总是如此：无药物压力下持续10年的蛋白酶抑制剂突变——一例病例报告 Layla Pagnucco and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2327–2330 32 Carbapenem resistance in Escherichia marmotae: characterization of IncL plasmids carrying blaOXA-48 土拨鼠埃希菌的碳青霉烯耐药性：携带blaOXA-48的IncL质粒特征 Astrid Rasmussen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2330–2331 Letters to the Editor(致编辑的信) 33 Comment on: Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a tertiary university hospital 述评：产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究 Jianjun Li and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2332 34 Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a Tertiary University Hospital—right to reply—author’s response 产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究——作者回复 Gulhadiye Avcu Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2332–2333 Corrections(更正) 35 Correction to: Sofosbuvir as post-exposure prophylaxis for yellow fever–associated viscerotropic disease (YEL-AVD) 更正：索非布韦作为黄热病相关内脏热带病（YEL-AVD）暴露后预防用药 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2334 36 Correction to: Pandemic human-associated extended-spectrum β-lactamase-producing Escherichia coli lineages of ST38, ST131 and ST141 identified in Viennese dogs 更正：维也纳犬体内发现与人相关的大流行性产超广谱β-内酰胺酶大肠杆菌ST38、ST131和ST141谱系 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2335 37 Correction to: GP or ChatGPT? Ability of large language models (LLMs) to support general practitioners when prescribing antibiotics 更正：全科医生还是ChatGPT？大型语言模型（LLM）在全科医生开具抗生素处方时的辅助能力 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2336 Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2 抗菌化疗杂志 80卷增刊2期 https://academic.oup.com/jac/issue SUPPLEMENT (补充) CANWARD 2007-23 加拿大抗感染耐药监测项目（CANWARD）2007-2023年数据/报告 Foreword(前言) 1 The CANWARD studies: Canadian Antimicrobial Resistance Alliance (CARA) Canadian Hospital Ward Antibiotic Resistance Surveillance collection 加拿大抗感染耐药监测项目研究：加拿大抗微生物耐药联盟（CARA）加拿大医院病房耐药性监测数据集 James C Hurley and Jean-Yves Madec Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Page ii1 Supplement Papers(补充论文) 2 Seventeen years of the CANWARD study (2007–23) 加拿大抗感染耐药监测项目研究17年（2007-2023年） George G Zhanel and Heather J Adam Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii2–ii4 3 Gram-positive pathogens from Canadian hospitals: 17years of results from the CANWARD study (2007–23) 来自加拿大医院的革兰氏阳性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023） George G Zhanel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii5–ii14 4 Gram-negative pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007–23) 来自加拿大医院的革兰氏阴性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023） George G Zhanel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii15–ii26 5 Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007–23) 加拿大医院耐甲氧西林金黄色葡萄球菌的特征：加拿大抗感染耐药监测项目研究的17年（2007-2023） Anissa Brahami and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii27–ii34 6 Comparison of antimicrobial resistance and serotype patterns in Streptococcus pneumoniae from blood cultures and respiratory specimens in Canadian hospitals from the CANWARD study (2007–23) 加拿大抗感染耐药监测项目研究中加拿大医院血液培养和呼吸道标本中肺炎链球菌抗微生物药物耐药性和血清型的比较（2007-23） Heather J Adam and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii35–ii44 7 Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007–23 加拿大医院中产生ESBL的大肠杆菌和肺炎克雷伯菌的比率增加：加拿大抗感染耐药监测项目研究17年，2007-2023 Philippe Lagacé-Wiens and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii45–ii53 8 Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007–23) 加拿大医院耐厄他培宁肠杆菌的特征：17年的加拿大抗感染耐药监测项目研究（2007-23） Laura F Mataseje and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii54–ii61 9 Characterization of carbapenem-resistant Pseudomonas aeruginosa in Canadian hospitals: 6years of the CANWARD study (2018–23) 加拿大医院耐碳青霉烯假单胞菌的特征：6年的加拿大抗感染耐药监测项目研究（2018-23） Melissa McCracken and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii62–ii71 10 Distribution and antimicrobial susceptibility profile of pathogens recovered from the bloodstream of Canadian patients: results from the CANWARD study (2007–23) 加拿大患者血液中病原菌的分布和药敏特征：来自加拿大抗感染耐药监测项目研究（2007-23）的结果 Andrew Walkty and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii72–ii82 Journal of Antimicrobial Chemotherapy Volume 80, Issue 9抗菌化疗杂志 80卷 9期 https://academic.oup.com/jac/issue VIEWPOINT（观点） 1 Classifying patients with invasive fungal disease: towards a unified case definition? 侵袭性真菌病患者分类：能否达成统一的病例定义？ Mehmet Ergün and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2337–2343, SYSTEMATIC REVIEW（系统综述） 2 Efficacy and safety of earlier switching to an oral antibiotic therapy for the treatment of Gram-positive bloodstream infections: a systematic review and meta-analysis 早期转换为口服抗生素治疗革兰氏阳性菌血流感染的疗效和安全性：一项系统综述和荟萃分析 ZhaoYi Tan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2344–2360, ORIGINAL RESEARCH（论著） 3 Determination of epidemiological cut-off values for Narasin, Salinomycin, Lasalocid and Monensin in Enterococcus faecium 屎肠球菌中那拉霉素、盐霉素、拉沙洛西钠和莫能菌素流行病学临界值的测定 Maria Laura Ferrando and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2361–2368, 4 Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era 四类耐药HIV感染者体内CXCR4嗜性病毒的持续存在及其在现代抗逆转录病毒治疗时代的临床影响 Rebecka Papaioannu Borjesson and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2369–2374, 5 Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeks 随机试验中96周内使用多替拉韦或对照抗逆转录病毒疗法对高血压和血压变化的影响 Parul Patel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2375–2383, 6 Comparative analysis of lipid profile changes in treatment-naïve people living with HIV on INSTI-based single-tablet regimens, BIC/FTC/TAF and DTG/3TC: real-world evidence from South Korea 基于整合酶抑制剂的单片复方制剂BIC/FTC/TAF和DTG/3TC在韩国初治HIV感染者中血脂谱变化的比较分析：来自现实世界的证据 So Yun Lim and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2384–2390, 7 A novel multilocus sequence typing scheme for Morganella spp.: population structure and introduction of quantitative metric for standardization of MLST scheme 摩根氏菌属的一种新型多位点序列分型方案：群体结构及引入用于标准化多位点序列分型方案的定量度量标准 Aymeric Jacquemin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2391–2398, 8 Genomic characterization of multidrug-resistant extended-spectrum β-lactamase-producing Vibrio cholerae O1 strains from 2022 cholera outbreak in Kenya 2022年肯尼亚霍乱疫情中产超广谱β-内酰胺酶的多重耐药霍乱弧菌O1株的基因组特征 Diana Imoli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2399–2407, 9 Impact of empiric anti-VRE therapy on survival in vancomycin-resistant enterococcal bloodstream infection 经验性抗万古霉素耐药肠球菌治疗对万古霉素耐药肠球菌血流感染患者生存率的影响 Tao-Hung Ou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2408–2416, 10 Safety of topical tobramycin powder during operative treatment of fractures 骨折手术中使用局部妥布霉素粉末的安全性 Gregory M Schrank and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2417–2420, 11 Trimethoprim/sulfamethoxazole and risk of haemophagocytic lymphohistiocytosis (HLH): a literature review and disproportionality analysis using individual case safety reports from FAERS 复方磺胺甲恶唑与噬血细胞性淋巴组织细胞增多症（HLH）的风险：基于FAERS数据库个案安全报告的文献综述和比例失衡分析 Rinko Lau and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2421–2427, 12 Highly drug-resistant Vibrio cholerae harbouring blaPER-7 isolated from travellers returning to England 从返回英国的旅行者中分离出携带blaPER-7基因的高度耐药霍乱弧菌 Satheesh Nair and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2428–2432, 13 Overcoming antimicrobial resistance in Helicobacter pylori: the roles of collateral sensitivity and biofilm dynamics 克服幽门螺杆菌的抗菌药物耐药性：附带敏感性和生物膜动态的作用 Siddharth Singh and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2433–2441, 14 Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae 四种未接触过但对头孢地尔耐药的产NDM肺炎克雷伯菌所致血流感染的临床和微生物学分析 Maria Mazzitelli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2442–2446, 15 Synergistic effects of DHA27 combined with gentamicin against methicillin-resistant Staphylococcus aureus in vitro and in vivo DHA27与庆大霉素联合对耐甲氧西林金黄色葡萄球菌的体内外协同作用 Xuemin Chen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2447–2458, 16 A multicentre study for determination of epidemiological cut-off values for Candida auris with EUCAST broth microdilution reference methodology 采用EUCAST肉汤微量稀释参考方法进行耳念珠菌流行病学临界值的多中心测定研究 Joseph Meletiadis and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2459–2465, 17 Impact of vancomycin resistance on attributable mortality among Enterococcus faecium bloodstream infections: propensity score analysis of a large, multicentre retrospective study 万古霉素耐药对屎肠球菌血流感染归因死亡率的影响：一项大型多中心回顾性研究的倾向评分分析 M Del Monte and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2466–2473, 18 Dynamics of dual CMV and EBV co-reactivation and emergence of resistance in an HSCT recipient 异基因造血干细胞移植受者中CMV和EBV双重再激活的动态变化及耐药性的出现 Martyna Pociupany and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2474–2483, 19 Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy 意大利米兰多西环素暴露后预防（DoxyPEP）使用者中用于治疗细菌性性传播感染的抗菌药物使用情况 Angelo Roberto Raccagni and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2484–2486, 20 Comparing the mortality of patients with sepsis using empirical piperacillin/tazobactam and cefepime: analysis of the MIMIC-IV database 使用经验性哌拉西林/他唑巴坦和头孢吡肟的脓毒症患者死亡率比较：基于MIMIC-IV数据库的分析 Yongseop Lee and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2487–2495, 21 Transmitted drug resistance profiles among people living with HIV-1 in Henan province, China, 2024 2024年中国河南省HIV-1感染者传播耐药情况 Jinjin Liu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2496–2502, 22 Fluctuations in copy number of the class A carbapenemase gene blaFRI appear to confer high-level carbapenem resistance A类碳青霉烯酶基因blaFRI拷贝数的波动似乎赋予了高水平碳青霉烯耐药性 Makiko Noda and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2503–2512, 23 In vitro activity of ceftobiprole plus ampicillin against Enterococcus faecalis causing infective endocarditis: phenotypic and genotypic characterization 头孢比罗联合氨苄西林对引起感染性心内膜炎的粪肠球菌的体外活性：表型和基因型特征 Clara Moretó-Castellsaguéand others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2513–2523, 24 Paradoxical interaction between dalbavancin and β-lactams against endocarditis-associated Enterococcus faecalis clinical isolates 达巴万星与β-内酰胺类药物对心内膜炎相关粪肠球菌临床分离株的矛盾相互作用 David Luque Paz and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2524–2529, 25 Comparative evaluation of broth microdilution and gradient diffusion methods in Burkholderia cepacia complex susceptibility testing: implications of transitioning to ECV-based interpretation 伯克霍尔德菌复合群药敏试验中肉汤微量稀释法和梯度扩散法的比较评估：向基于ECV解释转变的影响 Wenjie Cui and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2530–2540, 26 Strengthening antimicrobial resistance diagnostics in National Reference Laboratories across One Health in South and Southeast Asia: impact of external quality assessment and targeted follow-up 加强南亚和东南亚“同一健康”国家参考实验室的抗菌药物耐药性诊断能力：外部质量评估和针对性随访的影响 Freshwork Ayalew Abegaz and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2541–2549, RESEARCH LETTERS（研究快信） 27 TDM-guided meropenem/vaborbactam-based therapy for successful treatment of intra-abdominal and bloodstream infection caused by KPC-producing ceftazidime/avibactam-resistant Klebsiella pneumoniae in a paediatric liver transplant recipient 治疗药物监测指导下的美罗培南/瓦博巴坦疗法成功治疗儿童肝移植受者中产KPC且对头孢他啶/阿维巴坦耐药的肺炎克雷伯菌引起的腹腔和血流感染 Giovanni Mulé and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2550–2552, 28 Novel tmexC7D2-toprJ5 gene cluster and transposon Tn7759 carrying blaVIM-2 and blaOXA-10 genes in a carbapenem-resistant Pseudomonas putida from urban sewage 城市污水中碳青霉烯耐药恶臭假单胞菌中携带blaVIM-2和blaOXA-10基因的新型tmexC7D2-toprJ5基因簇和转座子Tn7759 Xinyuan Qiu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2552–2555, 29 Characterization of multiresistance gene optrA in Bacillus subtillis from China 中国枯草芽孢杆菌中多重耐药基因optrA的特征分析 Yongliang Che and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2555–2557, 30 Genomic characterization of a multidrug-resistant Mammaliicoccus sciuri strain isolated from urine of a patient from China 从中国患者尿液中分离出的一株多重耐药马氏鼠球菌的基因组特征 Fuqiang Ye and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2558–2560, LETTERS TO THE EDITOR（致编辑的信） 31 Comment on: Isavuconazole therapeutic drug monitoring and association with adverse events 关于“艾沙康唑治疗药物监测及其与不良反应的关联”的评论 Mi Zhou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2561–2562, 32 Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalised patients with pneumonia: a nationwide retrospective cohort study 关于“住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究”的评论 Satoru Mitsuboshi Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Page 2563, 33 Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—authors’ response 住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究——作者回复 Jumpei Taniguchi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2563–2564, Journal of Antimicrobial Chemotherapy Volume 80, Issue 10抗菌化疗杂志 80卷 10期 https://academic.oup.com/jac/issue REVIEWS（综述） 1 Long-acting cabotegravir and rilpivirine for the treatment of people with HIV: current landscape and challenges ahead 长效卡博特韦和利匹韦林治疗HIV感染者的现状与未来挑战 Luis Buzón-Martín and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2565–2586, 2 Systematic reviews and the Journal of Antimicrobial Chemotherapy; past, present and future. A systematic reappraisal 系统综述与《抗菌化疗杂志》：过去、现在与未来——系统再评估 James C Hurley Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2587–2596, SYSTEMATIC REVIEWS（系统综述） 3 Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology 研究肺结核治疗的肺内药代动力学：方法学的系统综述 Isabella van der Feltz and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2597–2608, 4 Global prevalence of nitrofurantoin-resistant uropathogenic Escherichia coli (UPEC) in humans: a systematic review and meta-analysis 全球人类中耐呋喃妥因的尿路致病性大肠埃希菌（UPEC）流行率：系统综述与荟萃分析 Christopher Larkin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2609–2621, ORIGINAL RESEARCH（研究论著） 5 Is ampicillin plus cephalosporins a therapeutic option for Ampicillin-Susceptible Enterococcus faecium? 氨苄青霉素联合头孢菌素是否为氨苄青霉素敏感的粪肠球菌的治疗选择？ Paula Bierge and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2622–2629, 6 Therapeutic efficacy monitoring of pyronaridine–artesunate (Pyramax®) in treating uncomplicated Plasmodium falciparum malaria in Gia Lai province, Vietnam from 2022 to 2023 2022-2023年越南嘉莱省青蒿琥酯-吡咯尼抗（Pyramax®）用于无并发症恶性疟原虫疟疾的治疗效果监测 Nguyen Van Thanh and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2630–2634, 7 Effectiveness of piperacillin/tazobactam loading dose for extended infusion dosing among patients with Gram-negative bacteraemia 哌拉西林/他唑巴坦负荷剂量用于革兰氏阴性菌血症患者延长输注给药的有效性 Savan Patel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2635–2643, 8 Intrapulmonary concentrations of ceftobiprole high doses administered by continuous infusion in critically ill patients with community-acquired pneumonia 连续输注大剂量头孢比罗在社区获得性肺炎危重患者中的肺内浓度 Claire Roger and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2644–2653, 9 Cefixime versus benzathine penicillin G for the treatment of early syphilis—a randomized, controlled open label trial 头孢克肟与苄星青霉素G治疗早期梅毒的随机对照开放标签试验 Tamara Klementová and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2654–2658, 10 Trends in antifungal use among hospitalized patients in the USA, 2018–23 2018-2023年美国住院患者抗真菌药物使用趋势 Dallas J Smith and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2659–2664, 11 Clinical impact of the BCID2 and rapid AST VITEK® REVEALTM on antibiotic optimisation in critically ill patients with Gram-negative bloodstream infections: a quasi-experimental pre/post interventional study BCID2和快速AST VITEK® REVEALTM对革兰氏阴性菌血流感染危重患者抗生素优化的临床影响：一项准实验性前后干预研究 Louis Oudiane and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2665–2675, 12 In vitro activity of thiamphenicol against drug-susceptible and drug-resistant strains of Mycoplasma genitalium 甲砜霉素对药物敏感和耐药生殖支原体菌株的体外活性 Sofie Skovmand and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2676–2681, 13 A priori optimization of levofloxacin dose regimen based on a population pharmacokinetics model 基于群体药代动力学模型的左氧氟沙星剂量方案先验优化 Emmanuel Enard and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2682–2692, 14 Model-informed individualized administration of ceftazidime–avibactam in critically ill patients: population pharmacokinetics studies and a parametric time-to-event analysis 危重患者头孢他啶-阿维巴坦的模型知情个体化给药：群体药代动力学研究和参数时间事件分析 Tingting Wu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2693–2704, 15 Development of blood culture time-to-positivity as a pharmacodynamic indicator for monitoring antibiotic therapy against MDR Gram-negative bacteria 开发血培养阳性时间作为监测针对多重耐药革兰氏阴性菌抗生素治疗的药效动力学指标 Irene Zaghi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2705–2713, 16 In vivo activity of ceftibuten-ledaborbactam oral combination against serine-β-lactamase-producing Enterobacterales: an assessment in the pyelonephritis and cystitis murine model 头孢布坦-莱达博巴坦口服联合用药对产丝氨酸-β-内酰胺酶肠杆菌科细菌的体内活性评估：在肾盂肾炎和膀胱炎小鼠模型中的评估 Christina Koenig and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2714–2718, 17 Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial 健康受试者静脉注射后口服奥马环素的粪便药代动力学、微生物组和胆汁酸变化：一项1期临床试验 Jinhee Jo and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2719–2726, 18 Interlaboratory comparison of a dried blood spot assay for antiretroviral adherence: implications for clinical application 抗逆转录病毒治疗依从性干血斑检测法的实验室间比对：对临床应用的启示 Nathan Engel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2727–2731, 19 A multicentre real-life prospective cohort study on effectiveness, durability and safety of long-acting injectable cabotegravir and rilpivirine in northern Italy: the LONGITUDE study 意大利北部长效注射用卡博特韦和利匹韦林有效性、持久性和安全性的现实中多中心前瞻性队列研究：LONGITUDE研究 Maria Mazzitelli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2732–2741, 20 Assessment of the risk of developing cefepime-induced abnormal liver enzyme levels using the albumin–bilirubin score and fibrosis-4 index: a single-centre retrospective case–control study 使用白蛋白-胆红素评分和纤维化-4指数评估头孢吡肟诱导的肝酶水平异常发生风险：一项单中心回顾性病例对照研究 Hiroki Katsu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2742–2751, 21 Clinical course of patients with bloodstream infections enrolled in the BALANCE clinical trial BALANCE临床试验中血流感染患者的临床病程 Sean W X Ong and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2752–2758, 22 Comparative outcomes of polymyxins in neurocritical care patients with carbapenem-resistant Gram-negative bacterial pneumonia: a retrospective cohort study 神经重症患者中多黏菌素治疗碳青霉烯类耐药革兰氏阴性菌肺炎的结果比较：一项回顾性队列研究 Qian Zeng and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2759–2772, 23 Distinct population structure and genomic context of NarAB between broiler and human clinical Enterococcus isolates 肉鸡和人类临床分离的粪肠球菌中NarAB的不同群体结构和基因组背景 Jayanth Balakuntla and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2773–2781, 24 Population pharmacokinetics of bictegravir in real-world people with HIV 现实中HIV感染者比克替拉韦的群体药代动力学 Pierre Ekobena and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2782–2789, 25 Rifampicin concentrations throughout the entire treatment duration of active tuberculosis; impact of sex and body mass index 活动性肺结核整个治疗期间利福平浓度：性别和体重指数的影响 Teres Samuelsson and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2790–2798, 26 Performance of disc diffusion and gradient strip test on different Mueller–Hinton agar media plates and ComASP® and Bruker UMIC® Cefiderocol Microdilution Panels for cefiderocol susceptibility testing in carbapenem-resistant Pseudomonas aeruginosa 在碳青霉烯类耐药铜绿假单胞菌中对头孢地尔敏感性测试使用不同穆勒-欣顿琼脂培养基平板和ComASP®及Bruker UMIC®头孢地尔微量稀释板的纸片扩散法和梯度条带测试的性能 Stefano Mancini and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2799–2806, 27 Placental transfer of medications to treat COVID-19, molnupiravir, favipiravir and nirmatrelvir/ritonavir, in the ex vivo human cotyledon model 在离体人类绒毛叶模型中治疗COVID-19的药物莫努匹拉韦、法维拉韦和奈玛特韦/利托那韦的胎盘转移 Solene Labaye and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2807–2813, 28 Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms 针对具有多种耐药机制的高度耐药鲍曼不动杆菌患者分离株的含头孢地尔抗生素联合用药的协同作用 Justin Halim and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2814–2824, 29 Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015–22: experience from an HIV clinic in Paris, France 2015-2022年药物减量抗逆转录病毒策略的采用情况及对成本的影响：来自法国巴黎一家HIV诊所的经验 L Sagaon-Teyssier and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2825–2833, 30 Molecular characterization of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae susceptible to delafloxacin 对达拉氟沙星敏感的侵袭性临床肺炎链球菌分离株中氟喹诺酮耐药性的分子特征 Emilia Cercenado and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2834–2843, 31 Genomic structure of class 1 and 2 integrons in non-typhoidal Salmonella isolated from food animals and related meat products in the USA 美国食品动物及其相关肉类产品中分离的非伤寒沙门氏菌1类和2类整合子的基因组结构 Chih-Hao Hsu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2844–2853, 32 Characterization of blaOXA-542-mediated carbapenem resistance in Acinetobacter baumannii 鲍曼不动杆菌中blaOXA-542介导的碳青霉烯类耐药性的特征 Jingchen Hao and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2854–2861, 33 Phenotypic and genotypic profiles of clinical isolates of various Nocardia species to carbapenems and fluoroquinolones 各种诺卡氏菌属临床分离株对碳青霉烯类和氟喹诺酮类的表型和基因型特征 Jing Yang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2862–2872, RESEARCH LETTERS（研究快报） 34 Oritavancin in a patient with recurrent endocarditis by Enterococcus faecalis: a new therapeutic option? 奥利他万星治疗粪肠球菌复发性心内膜炎患者：一种新的治疗选择？ Giulia Turicchi and Marco Bongiovanni Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2873–2874, 35 The catA1 chloramphenicol resistance gene originated in Atlantibacter hermannii catA1氯霉素耐药基因起源于大西洋菌属赫尔曼尼菌 Robert A Moran and Ruth M Hall Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2874–2876, 36 Horizontal transmission of a multidrug-resistant IncM1 plasmid harbouring blaOXA-48 and blaCTX-M-14b among patient microbiotas 携带blaOXA-48和blaCTX-M-14b的多重耐药IncM1质粒在患者微生物群中的水平传播 Roberto Sierra and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2876–2879, 37 Antimicrobial activity of temocillin on ceftriaxone-resistant and ceftriaxone-susceptible isolates of Neisseria gonorrhoeae 替莫西林对头孢曲松耐药和头孢曲松敏感淋病奈瑟菌分离株的抗菌活性 Julie Brousseau and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2879–2881, LETTERS TO THE EDITOR（致编辑的信） 38 Comment on: Bactericidal activity of antibiotic combinations against clinical isolates of Enterococcus gallinarum and Enterococcus casseliflavus 述评：抗生素联合用药对临床分离的鸡肠球菌和粪肠球菌的杀菌活性 Karl Oldberg and Magnus Rasmussen Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2882–2883, 39 Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study 述评：住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究 Giancarlo Ceccarelli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2884–2885, 40 Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—right to reply—authors’ response 住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究——作者回应权——作者回复 Jumpei Taniguchi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2885–2886, Journal of Antimicrobial Chemotherapy Volume 80, Issue Supplement_4抗菌化疗杂志 80卷增刊4期 https://academic.oup.com/jac/issue/80/Supplement_4 SUPPLEMENT（补充） Two Decades of BSAC Resistance Surveillance 英国抗菌化疗学会二十年耐药性监测 FOREWORD（前言） 1 Two Decades of BSAC Resistance Surveillance 英国抗菌化疗学会二十年耐药性监测 James C Hurley and Alan P Johnson Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Page iv1, SUPPLEMENT PAPERS（补充论文） 2 Two decades of resistance surveillance by the British Society for Antimicrobial Chemotherapy: design, development, delivery, deficiencies and future directions 英国抗菌化疗学会二十年耐药性监测：设计、发展、实施、不足与未来方向 Alasdair P MacGowan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv2–iv6, 3 The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: methods and limitations 英国抗菌化疗学会耐药性监测项目：方法与局限性 Michael Allen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv7–iv21, 4 Antimicrobial resistance among Gram-positive agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019 英国和爱尔兰地区革兰氏阳性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv22–iv35, 5 Antimicrobial resistance among Gram-negative agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019 英国和爱尔兰地区革兰氏阴性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv36–iv48, 6 Antimicrobial resistance among agents of hospital-acquired lower respiratory tract infection in the UK and Ireland: trends from 2008/2009 to 2018/2019 英国和爱尔兰地区医院获得性下呼吸道感染病原体的抗菌药物耐药性趋势（2008/2009 - 2018/2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv49–iv59, 7 Antimicrobial resistance among agents of community-associated lower respiratory tract infection in the UK and Ireland: trends from 1999/2000 to 2018/2019 英国和爱尔兰地区社区获得性下呼吸道感染病原体的抗菌药物耐药性趋势（1999/2000 - 2018/2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv60–iv71, 8 Trends of serotypes and resistance among Streptococcus pneumoniae in the UK and Ireland (1999–2019) 英国和爱尔兰地区肺炎链球菌血清型及耐药性趋势（1999 - 2019年） Carolyne Horner and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv72–iv86, 9 Applications and benefits of the British Society for Antimicrobial Chemotherapy Resistance Surveillance Project—legacy and future 英国抗菌化疗学会耐药性监测项目的应用与益处——成果与未来 Benjamin J Parcell and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv87–iv95, Journal of Antimicrobial Chemotherapy Volume 80, Issue 11抗菌化疗杂志 80卷 11期 https://academic.oup.com/jac/issue VIEWPOINTS（观点） 1 Modification of antimicrobial susceptibility testing methods 抗菌药物敏感性检测方法的修改 Ian Morrissey and Jean B Patel Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2887–2888, 2 Viewpoint: global antimicrobial stewardship accreditation is needed: the experience in Kentucky, USA 观点：需要建立全球抗菌药物管理认证体系：美国肯塔基州的经验 Ashley M Wilde and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2889–2891, REVIEWS（综述） 3 Phages connect the biological dots of antimicrobial resistance: from genesis and spread to alternative treatment modules 噬菌体揭示抗菌药物耐药性的生物学脉络：从起源与传播到替代治疗模式 Cleo Anastassopoulou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2892–2901, 4 Molecular drivers of fusion plasmid: mechanistic insights and evolutionary implications 融合质粒的分子驱动因素：机制见解与进化意义 Ziyi Liu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2902–2911, ORIGINAL RESEARCH（研究论著） 5 Emergence of livestock-associated MRSA clonal complex 398 in Thailand’s swine industry 泰国养猪业中出现与牲畜相关的MRSA克隆复合体398 Pawarut Narongpun and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2912–2917, 6 Peripheral neuropathy during long-term suppressive therapy with tedizolid: a case series 长期使用替达拉韦抑制治疗期间出现周围神经病变：系列病例报告 Tomaso Beringheli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2918–2922, 7 Low bacterial metabolism as a central mechanism of antimicrobial resistance and potential therapeutic target of staphylococcal biofilms in ventricular assist device driveline infections 细菌低代谢作为抗菌药物耐药性的核心机制及心室辅助装置驱动线感染中葡萄球菌生物膜的潜在治疗靶点 Yao Sun and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2923–2933, 8 The pivotal role of acnA in linking carbon metabolism to virulence and antimicrobial resistance in methicillin-resistant Staphylococcus aureus acnA在连接碳代谢与耐甲氧西林金黄色葡萄球菌的毒力和抗菌药物耐药性中的关键作用 Jiahui Li and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2934–2944, 9 Pharmacokinetics of rifampicin and isoniazid in patients with HIV–tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292–RIFAVIRENZ sub-study 接受以依非韦伦为基础的抗逆转录病毒治疗的HIV-结核病共感染患者中利福平和异烟肼的药代动力学：ANRS12292-RIFAVIRENZ子研究 Thibaut Gelé and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2945–2953, 10 Novel mutations associated with clofazimine resistance in Mycobacterium intracellulare 胞内分枝杆菌中与氯法齐明耐药相关的新型突变 Xiuzhi Jiang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2954–2957, 11 Physiologically informed in vitro framework reveals context-dependent combinatory activity of niclosamide–colistin against Gram-negative bacteria 基于生理信息的体外框架揭示了针对革兰氏阴性菌的硝基咪唑-多粘菌素组合的情境依赖性活性 Mariana Romero-Gonzalez and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2958–2969, 12 In vitro evolution provides insights into mechanisms of Mycoplasma genitalium resistance to moxifloxacin 体外进化揭示生殖支原体对莫西沙星的耐药机制 Teck-Phui Chua and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2970–2977, 13 The toxin–antitoxin system SavRS contributes to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus by mediating cell wall thickening 毒素-抗毒素系统SavRS通过介导细胞壁增厚促进万古霉素中间型金黄色葡萄球菌对万古霉素的耐药性 Weifeng Xu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2978–2988, 14 Molecular insights into carbapenemase-producing Enterobacterales from Senegal 塞内加尔产碳青霉烯酶肠杆菌目细菌的分子特征 Ousmane Sow and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2989–3000, 15 Population pharmacokinetic model of linezolid and its metabolite PNU-142300 in elderly patients 老年患者中利奈唑胺及其代谢产物PNU-142300的群体药代动力学模型 Xianglong Chen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3001–3010, 16 In vitro activity of contezolid and other comparators against clinical Staphylococcus and Enterococcus: a multicenter study in China 在中国开展的一项多中心研究中，康替唑胺及其他对照药物对临床分离的金黄色葡萄球菌和肠球菌的体外活性 Rongqi Lu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3011–3020, 17 Co-existence of the oxazolidinone resistance genes cfr and optrA on a novel multiresistance plasmid from a methicillin-resistant Macrococcoides bohemicum strain 从一株耐甲氧西林的马科考代菌属波希米亚菌株中发现的携带恶唑烷酮耐药基因cfr和optrA的新型多重耐药质粒 Yao Zhu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3021–3025, 18 Multidrug resistance and recurrence in urinary bacteraemia among cancer patients 癌症患者中尿路菌血症的多药耐药性和复发情况 Ignacio Grafia and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3026–3033, 19 Rapid replacement of blaKPC variant in ST11 carbapenem-resistant and hypervirulent Klebsiella pneumoniae contributed to ceftazidime/avibactam resistance during severe in vivo infection 在严重的体内感染期间，ST11型碳青霉烯耐药且高毒力的肺炎克雷伯菌中blaKPC变体的快速替代导致头孢他啶/阿维巴坦耐药 Ping Yang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3034–3042, 20 Potential human health risk of carbapenem-non-susceptible Pseudomonas aeruginosa from companion animals 伴侣动物中碳青霉烯类不敏感铜绿假单胞菌对人类健康的潜在风险 Jirachaya Toyting-Hiraishi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3043–3056, 21 Assessment of an LC coupled with tandem MS (LC-MS/MS) tool in the detection of antimicrobial resistance mechanisms in Enterobacterales 液相色谱-串联质谱（LC-MS/MS）工具在检测肠杆菌目细菌抗菌药物耐药机制中的应用评估 Anna Witkowska and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3057–3064, 22 Multidrug efflux pumps and innate azole resistance of Mucor lusitanicus 毛霉属葡萄牙菌的多药外排泵及其固有唑类耐药性 Stephanie Toepfer and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3065–3078, 23 Ivermectin dosing for children under 2 years 2岁以下儿童的伊维菌素剂量 Wenyu Yang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3079–3081, 24 Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort 一线拉米夫定/多替拉韦抗逆转录病毒疗法在HIV感染者中的有效性：来自ICONA基金会队列的现实数据 Alessandra Vergori and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3082–3091, 25 Eligibility and factors associated with long-acting injectable cabotegravir-rilpivirine initiation in an urban academic HIV clinic 城市学术型HIV诊所中长效注射用卡博特韦-利匹韦林启动的资格及关联因素 Geoffroy Liegeon and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3092–3100, 26 Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry 在接受抑制性抗逆转录病毒治疗的高度治疗经验丰富和多药耐药个体中，HIV-1 DNA耐药演变的评估：来自PRESTIGIO登记处的纵向研究 D Armenia and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3101–3106, 27 Sequential antibiotic exposure restores antibiotic susceptibility 序贯抗生素暴露恢复抗生素敏感性 Farhan R Chowdhury and Brandon L Findlay Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3107–3117, 28 Dermatological adverse effects of doxycycline as post-exposure prophylaxis for sexually transmitted infections among men who have sex with men: real-world findings from a multicentre study 在男男性行为者中，使用多西环素作为性传播感染暴露后预防的皮肤科不良反应：一项多中心研究的现实发现 Ling-Ya Chen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3118–3122, 29 Phenotype–genotype discordance in antimicrobial resistance profiles of Gram-negative uropathogens recovered from catheter-associated urinary tract infections in Egypt 埃及导管相关尿路感染中分离的革兰氏阴性尿路病原菌抗菌药物耐药性表型-基因型不一致性 Mohamed Eladawy and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3123–3132, 30 How should APOBEC3-induced resistance mutations be considered in the management of antiretroviral therapy? 在抗逆转录病毒治疗管理中，应如何考虑APOBEC3诱导的耐药突变？ Marie Gilbert and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3133–3138, 31 In vitro evaluation of olorofim and antifungal combinations against Aspergillus and Candida species 奥洛芬和抗真菌药物组合对曲霉菌和念珠菌属的体外评价 Corinne Pinder and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3139–3149, 32 Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis 在侵袭性肺曲霉病小鼠模型中，泊沙康唑与奥洛芬之间的拮抗作用 Christopher A Darlow and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3150–3159, 33 High level of archived and circulating HIV-1 drug resistance mutations in adolescents with a detectable viremia in Cameroon 喀麦隆可检测到病毒载量的青少年中HIV-1药物耐药突变的存档和循环水平较高 Armando B D Djiyou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3160–3164, RESEARCH LETTERS（研究快讯） 34 SCY-247, a novel second-generation triterpenoid antifungal, demonstrates high in vitro activity against genetically diverse Candida auris isolates, including FKS1 mutants 新型第二代三萜类抗真菌药物SCY-247对包括FKS1突变体在内的多种基因型耳道假丝酵母菌显示出高体外活性 Bram Spruijtenburg and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3165–3166, 35 Drug–drug interactions between tirzepatide and antiretrovirals: time to reassess and reassure? 替西帕肽与抗逆转录病毒药物之间的药物-药物相互作用：是时候重新评估和安心了吗？ Andrea Poloni and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3167–3168, 36 Does the use of topical azoles have an impact on antifungal resistance? 局部使用唑类药物对抗真菌耐药性有影响吗？ Jean-Yves Maillard Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3168–3186, 37 Leakage of cabotegravir and rilpivirine in HIV patients receiving long-acting injectable antiretroviral therapy 接受长效注射用抗逆转录病毒治疗的HIV患者中卡博特韦和利匹韦林的泄漏情况 Samir Benkouiten and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3187–3188, CORRECTION（更正） 38 Correction to: Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae 更正：对四种产NDM且之前未接触过头孢地洛的耐药肺炎克雷伯菌引起的血流感染的临床和微生物学分析 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Page 3189, Journal of Antimicrobial Chemotherapy Volume 80, Issue 12抗菌化疗杂志 80卷 12期 https://academic.oup.com/jac/issue VIEWPOINT（观点） 1 Rifampicin as monotherapy for infections caused by Staphylococcus aureus: considerations for not applying ‘breakpoints in brackets’ 利福平单药治疗金黄色葡萄球菌感染：关于不应用“括号内折点”的考量 Sara E Boyd and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3191–3193, REVIEWS（综述） 2 The Achilles’ heel of the Trojan Horse? A systematic evaluation of cefiderocol susceptibility testing 特洛伊木马的致命弱点？头孢地尔药敏试验的系统评价 Deny Tsakri and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3194–3207, 3 Antifungal treatment strategies and their impact on resistance development in clinical settings 抗真菌治疗策略及其对临床环境中耐药性发展的影响 Norman Van Rhijn and P Lewis White Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3208–3226, ORIGINAL RESEARCH（论著） 4 Decrease in colistin resistance among young bovine and pig productions in France: relationship with colistin usage and stewardship measures 法国年轻牛和猪生产中多粘菌素耐药性的下降：与多粘菌素使用及管理措施的关系 Claire Chauvin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3227–3235, 5 Time to anti-cancer treatment resumption after SARS-CoV-2 infection in patients with active haematological diseases undergoing combined antiviral treatments 接受联合抗病毒治疗的活动性血液系统疾病患者感染SARS-CoV-2后恢复抗癌治疗的时间 E Matteini and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3236–3241, 6 From TRIO to one: simplification to bictegravir/emtricitabine/tenofovir alafenamide in highly treatment-experienced people living with MDR HIV 从三联疗法到单一疗法：在多重耐药HIV感染且治疗经验丰富的人群中简化使用比克替拉韦/恩曲他滨/丙酚替诺福韦 José L Casado and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3242–3247, 7 Effects of commonly used antibiotics on children’s developing gut microbiomes and resistomes in peri-urban Lima, Peru 秘鲁利马市郊常用抗生素对儿童发育中的肠道微生物组和耐药组的影响 Neha Sehgal and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3248–3256, 8 Frailty Index Laboratory (FI-Lab) as predictor of poor outcomes for intra-hospital multidrug-resistant Klebsiella pneumoniae bloodstream infections: a single-centre retrospective cohort study 衰弱指数实验室（FI-Lab）作为预测院内多重耐药肺炎克雷伯菌血流感染不良预后的指标：一项单中心回顾性队列研究 Carmen Pellegrino and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3257–3264, 9 Mechanisms of resistance to ceftazidime/avibactam in mutants derived in vitro from Klebsiella pneumoniae producing OXA-48-like enzymes 体外衍生的产OXA-48样酶肺炎克雷伯菌突变体对头孢他啶/阿维巴坦的耐药机制 T Blanco-Martín and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3265–3272, 10 Comparative evaluation of disc diffusion and broth microdilution methods for aztreonam/avibactam susceptibility testing in Enterobacterales 肠杆菌目中氨曲南/阿维巴坦药敏试验的纸片扩散法和肉汤微量稀释法的比较评价 Ioannis Baltas and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3273–3277, 11 Efficacy of topical hydrophilic gel of paromomycin combined with systemic or locally administered leishmanicidal drugs for treatment of experimental leishmaniasis caused by Leishmania (Viannia) braziliensis 硫酸巴龙霉素亲水性凝胶局部用药联合全身或局部使用杀利什曼原虫药物治疗巴西利什曼原虫（Viannia亚属）引起的实验性利什曼病的疗效 Líndicy Leidicy Alves and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3278–3287, 12 Population pharmacokinetics and dosing optimization of cefoselis in paediatric patients with haematological malignancies 血液系统恶性肿瘤患儿中头孢噻利的群体药代动力学及剂量优化 Jing-Rui Liu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3288–3296, 13 Therapeutic challenges in treating ESBL- and/or AmpC-producing non-carbapenemase-producing Enterobacterales: an in vitro evaluation of novel β-lactam/β-lactamase inhibitor combinations and cefiderocol 治疗产超广谱β-内酰胺酶（ESBL）和/或AmpC酶且不产碳青霉烯酶的肠杆菌目细菌的挑战：新型β-内酰胺/β-内酰胺酶抑制剂组合和头孢地尔的体外评价 Inès Rezzoug and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3297–3305, 14 Post-exposure prophylaxis with doxycycline (DoxyPEP) to prevent STIs in a real-world setting: the PRIDOX study 使用多西环素进行暴露后预防（DoxyPEP）以在现实环境中预防性传播感染：PRIDOX研究 R Palacios and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3306–3310, 15 Risk–benefit balance of blood cultures among patients with stage IV cancer in unplanned admission: a nationwide propensity score–weighted study in Japan 日本全国范围内倾向评分加权研究：IV期癌症患者非计划入院时血培养的风险-获益平衡 Yuki Hashimoto and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3311–3319, 16 A drug-repurposing screen of FDA- and EMA-approved drugs identifies two NF-κB inhibitors active against eumycetoma 对美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）批准的药物进行药物再利用筛选，发现两种对真性着色真菌病有活性的NF-κB抑制剂 Jingyi Ma and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3320–3328, 17 Temocillin versus other intravenous beta-lactams for urinary tract infections caused by third-generation cephalosporin-resistant Enterobacterales: a multicentre retrospective matched cohort study 替莫西林与其他静脉注射β-内酰胺类药物治疗第三代头孢菌素耐药肠杆菌目引起的尿路感染：一项多中心回顾性匹配队列研究 Jeanne Iachkine and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3329–3334, 18 Treatment preferences by infectious diseases clinicians for carbapenem-resistant Enterobacterales infections 感染科医生对碳青霉烯耐药肠杆菌目感染的治疗偏好 Samuel E Cincotta and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3335–3339, 19 The aphA1 kanamycin and neomycin resistance gene originated in Klebsiella michiganensis aphA1卡那霉素和新霉素耐药基因起源于密歇根克雷伯菌 Robert A Moran and Ruth M Hall Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3340–3344, 20 Global susceptibility profiles and potential resistance mechanisms of ceftazidime–avibactam-resistant, non-carbapenemase-producing carbapenem-resistant Enterobacterales: 2020–23 data from the Antimicrobial Testing Leadership and Surveillance 头孢他啶-阿维巴坦耐药且不产碳青霉烯酶的碳青霉烯耐药肠杆菌目的全球易感性特征和潜在耐药机制：2020-2023年来自抗菌药物测试领导与监测的数据 Chih-Cheng Lai and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3345–3351, 21 Comparative in vitro activity of ceftazidime-avibactam plus aztreonam and the fixed combination aztreonam/avibactam against multidrug-resistant Pseudomonas aeruginosa 头孢他啶-阿维巴坦联合氨曲南与固定组合氨曲南/阿维巴坦对多重耐药铜绿假单胞菌的体外活性比较 Sophie E Müller and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3352–3356, 22 Dual β-lactam synergy in Enterococcus faecalis and its relationship with penicillin-ceftriaxone infective endocarditis treatment outcomes 粪肠球菌中双重β-内酰胺协同作用及其与青霉素-头孢曲松感染性心内膜炎治疗结果的关系 April Gregson and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3357–3366, 23 The long walk to a short half-life: the discovery of augmented renal clearance and its impact on antibiotic dosing 走向短半衰期的漫长之路：发现肾增强清除及其对抗菌药物剂量调整的影响 Jeffrey Lipman and Russell E Lewis Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3367–3374, 24 Aztreonam-amoxicillin/clavulanate combination therapy against blaNDM-producing Enterobacterales infections 氨曲南-阿莫西林/克拉维酸联合治疗产blaNDM肠杆菌目感染 Efrat Orenbuch-Harroch and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3375–3380, 25 Evaluation of sodium zirconium cyclosilicate usage for hyperkalaemia secondary to sulfamethoxazole/trimethoprim therapy 评估锆酸钠环硅酸盐用于磺胺甲恶唑/甲氧苄啶治疗继发的高钾血症 Dixie Pyles and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3381–3385, 26 Thrice-weekly post-haemodialysis ceftazidime can achieve adequate pre-dialysis concentrations and clinical cure in patients with melioidosis 每周三次血液透析后使用头孢他啶可在类鼻疽患者中达到足够的透析前浓度并实现临床治愈 Simon Smith and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3386–3390, 27 In vitro and clinical data demonstrate negligible risk of drug–drug interactions with opelconazole, a novel inhaled antifungal agent 体外和临床数据表明，新型吸入抗真菌药物奥培康唑的药物-药物相互作用风险可忽略不计 Lindsey M R Cass and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3391–3400, 28 Antifungal prophylaxis in patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)–positive acute myeloid leukaemia receiving sorafenib during initial induction and consolidation treatment in ALLG AMLM16 trial 在ALLG AMLM16试验中，FLT3-ITD阳性急性髓系白血病患者在初始诱导和巩固治疗期间接受索拉非尼治疗时的抗真菌预防 Chin Fen Neoh and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3401–3406, 29 The synergistic activity of tigecycline-based combinations against multidrug-resistant Acinetobacter baumannii-caused bloodstream infections 基于替加环素的联合用药对多重耐药鲍曼不动杆菌引起的血流感染的协同活性 Huan Zhang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3407–3418, 30 Piperacillin dosing in pediatric patients and augmented renal clearance: are current guidelines sufficient to achieve therapeutic concentration coverage? 儿科患者中哌拉西林的剂量调整与肾增强清除：现行指南是否足以达到治疗浓度覆盖？ Anne Ravix and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3419–3430, 31 Efficacy of human-simulated aztreonam-avibactam against Stenotrophomonas maltophilia in the neutropenic murine thigh infection model 在中性粒细胞减少的小鼠大腿感染模型中评估人模拟氨曲南-阿维巴坦对嗜麦芽窄食单胞菌的疗效 Yakun Fu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3431–3437, 32 A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study) 西班牙HIV感染者长期使用卡博特韦和利匹韦林的有效性和持久性的前瞻性评估（RELATIVITY研究） Luis Buzón-Martín and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3438–3451, 33 Antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatus 奥洛罗芬和伏立康唑对烟曲霉的体外拮抗作用 Illan Laloum and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3452–3461, RESEARCH LETTERS（研究快讯） 34 Concomitant IV vancomycin causing delayed high-dose methotrexate clearance and acute kidney injury 静脉注射万古霉素联用导致大剂量甲氨蝶呤清除延迟和急性肾损伤 Thao Dao and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3462–3464, 35 Overestimation of piperacillin/tazobactam resistance in Escherichia coli by disc diffusion and gradient strip methods 纸片扩散法和梯度条法高估大肠埃希菌对哌拉西林/他唑巴坦的耐药性 Stefano Mancini and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3464–3467, 36 Mind the gap: missed re-initiation and monitoring in statin–antimicrobial co-prescriptions 注意差距：他汀类药物与抗菌药物联合处方中的漏重新起始和监测 Melwin Kyle Solis and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3467–3468, 37 Pharmacokinetics of aztreonam/avibactam in a critically ill patient with a class B metallo-β-lactamase producing Enterobacteriaceae and receiving continuous renal replacement therapy 一名接受连续肾脏替代治疗且感染产B类金属β-内酰胺酶肠杆菌科细菌的重症患者中氨曲南/阿维巴坦的药代动力学 Daniel Fresán and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3469–3471, CORRECTION（更正） 38 Correction to: Systematic reviews and the Journal of Antimicrobial Chemotherapy; past, present and future. A systematic reappraisal 更正：系统评价与《抗菌药物化疗杂志》：过去、现在和未来。一项系统再评价 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3472–3473,

2025-11-30

·百度百家

国药现代：从车间药香到国民药企，守护国人健康的化学药担当

家里老人的降压药瓶上印着“国药现代”，孩子发烧时吃的退烧药产自这里，就连医院手术中用的抗感染药物，很多也贴着它的标签。这个藏在我们健康生活方方面面的企业，不像保健品那样有噱头，却用一丸一药的实在，成为了国民健康的“隐形守护者”。上海现代制药股份有限公司（简称“国药现代”），如今是中国医药集团旗下的核心化学药平台，但追根溯源，它的起点是1965年上海郊区的几间简易厂房。从生产第一代青霉素针剂，到如今覆盖抗感染、心血管、代谢性疾病等十大治疗领域，从地方小厂到年生产数十亿片药剂的行业龙头，国药现代的故事，是中国化学制药工业从“依赖进口”到“自主保障”的奋斗史，更是一代代医药人“药为民安”的初心史。今天咱们就顺着药瓶上的生产日期，聊聊天药现代的故事。它没有网红品牌的流量光环，却靠着“质量过硬、疗效确切、价格亲民”站稳脚跟；它不搞概念炒作，却让“国药现代造”成为医生和患者都信赖的金字招牌。初创：车间里的“救命药”，为国人撑起用药底线（1965-1978年）国药现代的源头，要回到上世纪六十年代的上海。1965年，为了打破国外抗生素的垄断，解决老百姓“缺医少药”的困境，上海市医药局在闵行区建起了“上海第二制药厂”——这就是国药现代最直接的前身。那时候的中国，连普通的青霉素都要靠进口，一瓶青霉素的价格相当于普通工人半个月的工资，很多患者因为用不上药而耽误治疗。建厂初期的条件，只能用“白手起家”来形容。厂区是一片荒地，工人们先搭起油毛毡棚当临时车间，再从老药厂调来几台破旧的反应釜和离心机。没有自动化设备，溶解原料靠人工搅拌，分装药剂靠手工操作，就连灭菌用的蒸汽，都要靠烧煤锅炉供应。有位老工人回忆：“夏天车间里温度能到40℃，大家穿着厚工作服，汗顺着脊梁骨流，后背的盐渍能结一层，却没人敢脱，生怕污染药品。” 第一个攻坚任务，就是生产青霉素钠针剂。青霉素的生产对环境要求极高，一点杂菌污染就会导致整批原料报废。那时候没有无菌车间，工人们就用酒精反复擦拭墙壁和地面，戴着三层口罩和橡胶手套作业，连呼吸都要小心翼翼。菌种培养是核心技术，国内没有经验，技术人员就抱着从苏联引进的残缺资料，在临时实验室里反复试验。 1966年冬天，第一批次青霉素针剂成功下线。当透明的药液装进安瓿瓶，经过高温灭菌后，技术负责人张师傅颤抖着拿起一支，对着灯光看了又看：“这是咱们自己造的青霉素，以后老百姓用药不用再看外国人脸色了！”这批针剂很快送到了农村和基层医院，有位乡村医生说：“以前治肺炎，要托人从上海买进口青霉素，现在本地药厂就有，救了多少孩子的命啊。” 除了青霉素，工厂还承担了当时急需的磺胺类药物生产。这种药物能治疗多种细菌感染，是战地和农村的“万能药”。但磺胺药的原料合成过程中会产生刺激性气体，车间里没有专业的通风设备，工人们就用湿毛巾捂住口鼻继续工作。有位技术员因此患上了鼻炎，却笑着说：“只要能出药，这点毛病不算啥。” 文革期间，工厂的生产受到了冲击，但就算再乱，“保药品供应”的底线没破过。1972年，上海爆发流感，退烧药需求激增，工厂的工人们放弃了春节假期，24小时轮班生产。那时候没有自动包装机，女工们坐在流水线旁，双手不停地折叠药盒、装药片，手指磨出了水泡，缠上胶布接着干。她们说：“医院里病人等着药，我们多干一分钟，就有人能早一分钟退烧。” 到1978年改革开放前，工厂已经能生产青霉素、链霉素、磺胺类等8种常用抗感染药物，年产量达到5000万支（片），不仅供应上海，还通过铁路运往全国各地。虽然设备简陋、品种单一，但这家郊区小厂，已经成为了保障华东地区基层用药的重要力量。这十三年的初创时光，国药现代的前身就像一粒“希望的种子”，在缺药的年代里顽强生长，为中国化学制药工业埋下了“自主生产”的根。成长：从“仿制药”到“精制药”，跟着时代升级迭代（1979-2009年） 1978年改革开放后，中国的医药行业迎来了“春天”。随着人民生活水平的提高，对药品的需求从“有没有”转向“好不好”；同时，国外先进的制药技术开始进入中国，给国内药企带来了挑战，也带来了机遇。国药现代的前身，也从“计划生产”走向“市场竞争”，开始了从“仿制药”到“精制药”的升级之路。 1981年，工厂迎来了第一次技术革新——从德国引进了一套青霉素无菌生产线。这套设备能实现从原料溶解到灌装灭菌的全封闭操作，不仅生产效率提高了3倍，药品的纯度也大幅提升。当德国工程师来调试设备时，看到工人们用粉笔在地上画流程图、用算盘计算投料量，忍不住感叹：“你们用最原始的工具，做出了最严谨的药品。” 技术升级后，工厂的产品也开始丰富起来。1983年，研发出了头孢拉定胶囊——这是当时国内少有的第二代头孢菌素，抗菌效果比青霉素更强，副作用更小。研发过程中，为了攻克头孢菌素的结晶难题，技术团队在实验室里待了整整三个月，每天只睡四五个小时，最终确定了最佳的结晶温度和时间。这款药一上市就受到了医院的欢迎，当年的销售额就突破了千万元。 1988年，工厂更名为“上海现代制药厂”，正式确立了“现代制药”的品牌方向。这一时期，它开始从“抗感染药单一领域”向“多领域布局”拓展，重点研发心血管和消化系统药物。1990年，研发出了硝苯地平片——这是治疗高血压的常用药，以前全靠进口，价格昂贵。现代制药厂通过技术攻关，生产出的硝苯地平片，疗效和进口药相当，价格却只有一半，很快就占据了国内市场的半壁江山。 1995年，是国药现代发展史上的关键一年——它成为了国内首批通过“GMP认证”的制药企业。GMP是药品生产质量管理规范，对车间环境、设备精度、人员操作都有严格要求。为了通过认证，工厂投入了数千万元改造车间，安装了空气净化系统、自动投料设备和在线检测仪器。以前靠人工判断的药品纯度，现在通过电脑屏幕就能精准显示；以前手写的生产记录，现在变成了电子台账，可追溯、可核查。通过GMP认证后，现代制药厂的产品开始走向国际。1998年，它的头孢类药物通过了东南亚国家的药品认证，第一次出口到越南、泰国等国家。当第一批药品装船发运时，老厂长站在码头，看着印有“上海现代”字样的集装箱，激动地说：“咱们的药，终于走出国门了！” 2000年以后，中国的医药行业开始整合，现代制药厂也抓住了机遇。2004年，它完成了国有企业改制，成立了“上海现代制药股份有限公司”；2006年，在上海证券交易所上市，成为了“化学制药行业上市第一梯队”的企业。上市后，它加大了研发投入，在上海张江建了现代化的研发中心，引进了博士、海归等高端人才。 2008年，国药现代研发出了阿托伐他汀钙片——这是治疗高血脂的重磅药物，能有效降低心脑血管疾病的风险。为了达到和进口原研药完全一致的疗效，研发团队进行了上百次的体外溶出试验，最终让药品的生物等效性达到了99%。这款药上市后，迅速成为了临床首选，帮助无数高血脂患者控制了病情。到2009年底，国药现代已经拥有了抗感染、心血管、消化、内分泌四大类共50多种药品，年生产能力达到10亿支（片），产品覆盖了全国2000多家医院。从“上海郊区小厂”到“全国知名药企”，它用三十年的时间，完成了从“保障供应”到“品质竞争”的转变，成为了中国化学制药行业的中坚力量。融合：背靠国药集团，打造全产业链优势（2010-2020年） 2010年以后，中国的医药行业进入了“整合升级期”。国家开始推行“医药分开”“集中采购”等政策，鼓励药企做大做强、提升创新能力；同时，中国医药集团（简称“国药集团”）作为中央直属的医药健康产业平台，开始整合旗下的制药资源。2017年，国药现代正式并入国药集团，成为其核心化学药平台，这一融合，让它获得了全产业链的资源优势，迎来了跨越式发展。并入国药集团后的第一个大动作，就是“产能整合”。国药集团旗下有多家地方制药厂，国药现代通过技术输出和管理升级，将这些工厂整合为专业化的生产基地：上海基地专注于高端制剂，江苏基地生产原料药，安徽基地负责抗感染药物，四川基地聚焦心血管药物。这样的布局，既避免了重复建设，又形成了“原料药-制剂”的垂直产业链，大大降低了生产成本。 2018年，国家启动“仿制药质量和疗效一致性评价”，这是对国内仿制药的一次“大考”——要求仿制药必须和原研药在质量和疗效上完全一致。国药现代率先响应，投入5亿元开展一致性评价工作。以常用药盐酸二甲双胍片为例，为了达到原研药的释放速率，研发团队优化了片剂的辅料配比，进行了60多次试验，最终顺利通过评价。到2020年，国药现代有28个品种通过一致性评价，数量位居行业前列。这一时期，国药现代在“创新药研发”上也取得了突破。2019年，它自主研发的替加环素注射液获批上市——这是国内首个获批的新一代四环素类抗生素，针对多重耐药菌感染，填补了国内空白。研发这款药花了8年时间，光是临床试验就涉及全国30多家医院、2000多名患者。有位参与试验的感染科医生说：“以前遇到多重耐药菌感染的患者，几乎无药可医，替加环素的上市，给这些患者带来了希望。” 在保障民生用药方面，国药现代始终冲在前面。2016年，全国范围内出现“低价药断供”现象，很多常用的降压药、降糖药因为利润低，企业不愿生产。国药现代主动承担了12种低价药的生产任务，哪怕不赚钱，也要保障供应。比如每片几分钱的复方利血平片，它一直坚持生产，每年供应市场1亿片以上，解决了基层高血压患者的用药难题。 2020年新冠疫情爆发，国药现代更是第一时间投入“抗疫”。疫情初期，口罩、防护服紧缺，它的子公司紧急改造生产线，生产医用防护口罩；同时，全力保障抗病毒药物、解热镇痛药的生产。武汉封城期间，国药现代的物流车顶着风险，将一批批退烧药和抗感染药物送到武汉的医院。有位送药司机说：“看到医院门口等待药品的医护人员，就觉得再危险也值得。” 到2020年，国药现代已经拥有了10个生产基地、3个研发中心，产品覆盖十大治疗领域，共150多个品种，其中20多个品种进入国家医保目录。从“地方药企”到“国药集团核心平台”，它用十年的时间，完成了从“单打独斗”到“全产业链协同”的转变，成为了保障国家药品供应的“主力军”。现状：国民健康的“药箱管家”，全产业链的化学药龙头（2021-至今）如今的国药现代，早已不是当年的单一药厂，而是成为了一家“覆盖研发、生产、销售全产业链，聚焦化学药核心领域”的行业龙头。走进它的生产基地，你会看到：智能化的生产线在精准运转，机器人在无菌车间里完成药品包装，研发中心的科学家们在调试新的实验设备。现在的国药现代，就像一位专业的“药箱管家”，从儿童到老人，从常见病到疑难杂症，都能提供精准的用药解决方案。现在的国药现代，核心业务可以分成“四大板块”，每一个都和国民健康息息相关，共同构成了它的核心竞争力。第一个板块是“抗感染药物”——这是国药现代的“压舱石”业务，也是它的起家之本。现在它能生产从青霉素、头孢到碳青霉烯类的全系列抗感染药物，涵盖口服、注射等多种剂型。在江苏的生产基地，有国内最先进的头孢类药物生产线，实现了从原料药合成到制剂灌装的全自动化，每一支注射液的纯度都达到99.9%以上。2023年，它的抗感染药物销售额占比达到30%，是国内医院抗感染用药的主要供应商之一。第二个板块是“心血管与代谢性疾病药物”——这是国药现代的“增长引擎”。随着老龄化社会的到来，高血压、高血脂、糖尿病等慢性病患者越来越多，对相关药物的需求也日益增长。国药现代的这类药物已经形成了“全品类矩阵”：降压药有硝苯地平、缬沙坦等，降脂药有阿托伐他汀、瑞舒伐他汀等，降糖药有二甲双胍、格列美脲等。这些药物不仅疗效确切，而且通过集中采购，价格大幅降低，比如阿托伐他汀钙片，一片的价格不到一毛钱，大大减轻了患者的负担。第三个板块是“高端制剂与创新药”——这是国药现代的“技术高地”。高端制剂方面，它研发出了缓控释制剂、靶向制剂等新型剂型，比如硝苯地平控释片，能实现24小时平稳降压，患者每天只需服用一次，大大提高了用药依从性。创新药方面，除了已经上市的替加环素，还有5个一类创新药进入了临床试验阶段，涵盖肿瘤、自身免疫性疾病等领域。2023年，它的创新药研发投入占比达到8%，远超行业平均水平。第四个板块是“原料药与CDMO服务”——这是国药现代的“产业链优势”。它在江苏、浙江建有大型原料药生产基地，能为自身制剂生产提供稳定的原料供应，同时还为国内外药企提供原料药委托加工服务。CDMO服务则是为创新药企提供从药物研发到生产的全流程服务，帮助初创药企加快新药上市进程。2023年，它的CDMO业务已经服务了50多家创新药企，成为了行业内知名的“创新药孵化平台”。除了核心业务，国药现代的“数字化转型”也走在了行业前列。在上海的智能生产车间，安装了200多个传感器，能实时监控生产过程中的温度、湿度、压力等参数，一旦出现异常，系统会自动报警并调整；在研发中心，利用人工智能技术模拟药物分子结构，将新药研发的周期缩短了30%；在销售端，通过大数据分析不同地区的疾病谱，精准调配药品供应，避免了药品积压和短缺。作为央企旗下的药企，国药现代还积极承担社会责任。在“乡村振兴”中，它在云南、贵州等偏远地区开展“健康扶贫”活动，免费为村民提供体检和常用药；在“科普宣传”中，组织药师走进社区和学校，讲解合理用药知识，避免药物滥用；在“应急保障”中，建立了应急药品储备库，能在重大灾害和公共卫生事件中，第一时间调配药品。2023年，它被评为“全国医药行业社会责任标杆企业”。未来：锚定“创新”与“国际化”，做全球信赖的化学药企业（2024-未来）随着“健康中国2030”战略的推进，以及全球医药产业的变革，国药现代的未来规划越来越清晰，紧扣“创新驱动、国际化布局、高质量发展”三个关键词，目标是“成为全球信赖的化学药企业，为人类健康贡献中国力量”。第一个重点是“创新药研发的攻坚”。国药现代计划未来5年投入50亿元用于创新药研发，重点聚焦肿瘤、自身免疫性疾病、神经系统疾病三大领域。在肿瘤领域，研发针对肺癌、乳腺癌的靶向药物，这类药物能精准攻击癌细胞，减少对正常细胞的损伤；在自身免疫性疾病领域，研发治疗类风湿关节炎、银屑病的生物制剂，填补国内高端生物药的空白；在神经系统疾病领域，研发治疗阿尔茨海默病的药物，应对老龄化带来的健康挑战。为了加快创新药研发，国药现代采取了“自主研发+合作引进”的双轮驱动模式。一方面，加强内部研发团队建设，引进全球顶尖的医药科学家；另一方面，和国内外的高校、科研机构合作，比如与清华大学合作建立“药物化学联合实验室”，共同攻克核心技术。2024年，它的首个肿瘤靶向药已经进入三期临床试验，预计2026年能获批上市。第二个重点是“国际化布局的提速”。国药现代计划从“产品出口”向“全球运营”转型，在海外建设生产基地和研发中心。2024年，它在东南亚的越南建成了首个海外制剂生产基地，主要生产抗感染和心血管药物，服务东南亚市场；同时，在美国新泽西州设立了研发中心，招聘当地的研发人才，专注于创新药的国际临床试验。在国际认证方面，国药现代计划让更多产品通过美国FDA、欧洲EMA等权威认证，进入欧美高端市场。2024年，它的头孢类药物已经通过了美国FDA认证，开始进入美国的仿制药市场。虽然欧美市场竞争激烈，但国药现代有信心：“我们的药品在质量上和原研药相当，价格更有优势，一定能打开市场。” 第三个重点是“高端制剂的升级”。针对现在患者对“用药便捷性、安全性”的更高需求，国药现代计划研发更多新型制剂，比如口服速溶片，适合吞咽困难的老人和儿童；皮下注射微球制剂，一次注射能维持一个月的疗效，减少患者的注射次数；吸入制剂，用于治疗哮喘和慢性阻塞性肺疾病，能让药物直接作用于肺部，提高疗效。第四个重点是“数字化与智能化的深化”。国药现代计划打造“数字孪生工厂”，在电脑上搭建一个和真实生产基地一模一样的数字模型，通过人工智能技术模拟生产过程，优化生产参数，提高生产效率和产品质量。同时，建设“智慧供应链”体系，利用物联网技术实现药品从生产到患者手中的全流程追溯，确保药品的安全。2024年，它的上海生产基地已经实现了“黑灯工厂”运营，在没有人工干预的情况下，能24小时不间断生产。第五个重点是“聚焦民生需求，完善产品矩阵”。国药现代计划针对特殊人群研发专用药物，比如儿童专用的退烧药，调整剂型和口味，让孩子更容易接受；老年人专用的复方降压药，将多种药物成分整合，减少服药数量；孕妇专用的维生素补充剂，确保用药安全。同时，继续承担低价药、短缺药的生产任务，保障民生用药的底线。当然，国药现代也清楚未来的挑战：创新药研发风险高、周期长，失败率超过90%；全球医药行业竞争激烈，国外巨头在技术和品牌上有先发优势；药品集中采购政策下，企业的利润空间被压缩。为了应对这些挑战，国药现代制定了一系列措施：在研发上，加强专利布局，分散研发风险；在市场上，差异化竞争，突出自身在抗感染、心血管领域的优势；在成本上，通过规模化生产和数字化管理，降低生产成本。发展关键点：国药现代的“成长密码” 回顾国药现代近六十年的发展历程，从上海郊区的小药厂到全球布局的化学药龙头，它的成功不是偶然的，背后藏着一套独特的“成长密码”。这些密码不仅是国药现代的核心竞争力，也为中国医药企业的发展提供了宝贵的借鉴。关键点一：央企基因，把“责任”放在首位国药现代的根在央企，“保障药品供应、守护国民健康”的责任，从一开始就刻在了它的基因里。缺药年代生产救命药，疫情期间保障应急药，低价药断供时主动补位，它从来不是只追求利润的企业，而是把社会责任放在首位。这种责任担当，让它赢得了政府和社会的信任，在国家重大公共卫生事件中总能承担重任；也让它赢得了患者的认可，成为了老百姓心中的“放心药企”。关键点二：质量为本，把“严谨”刻进骨子里药品是“治病救人”的特殊商品，质量就是生命。国药现代从初创时的人工无菌操作，到现在的全流程数字化监控，六十年来始终把质量放在第一位。每一批药品都要经过几十项检测，每一个生产环节都有严格的标准，不合格的产品绝对不会出厂。这种对质量的极致追求，让它通过了国内外的各种权威认证，也让它的产品在临床中表现稳定，成为了医生首选的用药品牌。关键点三：创新驱动，跟着需求迭代升级医药行业是技术密集型行业，没有创新就没有未来。国药现代从仿制药起步，但从来没有停止创新的脚步：从引进国外技术，到自主研发仿制药，再到攻坚创新药；从单一抗感染药，到多领域布局，每一次升级都紧跟患者的需求和行业的趋势。这种“以需求为导向”的创新，让它的产品总能击中市场痛点，从激烈的竞争中脱颖而出。关键点四：整合协同，发挥全产业链优势并入国药集团后，国药现代最大的优势就是“全产业链协同”。从原料药生产到制剂加工，从研发到销售，从国内基地到海外布局，它形成了完整的产业链生态，既能降低成本，又能保障供应稳定。这种产业链优势，让它在集中采购和国际竞争中更有底气，也让它能快速响应市场变化，为患者提供更全面的用药解决方案。关键点五：贴近临床，把“患者”放在心上国药现代的产品，从来不是“闭门造车”，而是贴近临床需求研发的。医生反馈进口药价格高，它就研发平价仿制药；患者觉得服药麻烦，它就研发缓控释制剂；老人和孩子吞咽困难，它就研发口服速溶片。这种“以患者为中心”的产品策略，让它的药品更接地气，更受市场欢迎，也让它的品牌真正走进了老百姓的生活。结语：从车间药香到全球舞台，守护健康的初心不变从1965年上海郊区的第一瓶青霉素，到如今全球患者手中的各类药物，国药现代用近六十年的时间，书写了一段中国化学制药工业的奋斗史。它没有惊天动地的传奇，只有“做好每一粒药”的坚守；没有华丽的宣传，只有“药为民安”的务实；没有忘记自己的根，始终带着央企的责任和医药人的初心。这家从上海走出的药企，陪着中国医药行业从“缺医少药”走到“自主保障”，从“仿制药大国”走向“创新药强国”，它的成长，是中国医药工业发展的缩影。如今，在健康中国战略和全球医药变革的浪潮中，国药现代已经站在了新的起跑线上。我们有理由相信，这家带着央企担当的化学药龙头，必将在未来的全球舞台上绽放更耀眼的光芒，用更多优质、安全、平价的药品，守护更多人的健康，为人类健康事业贡献属于中国的力量。

高管变更

2025-11-25

·噬界真奇妙

【与噬俱进|FICAIM】决战多重耐药肺炎克雷伯菌——从耐药机制的分子迷宫到噬菌体联合疗法的临床突围

Ding, J., et al., Combating Klebsiella pneumoniae: from antimicrobial resistance mechanisms to phage-based combination therapies. Frontiers in Cellular and Infection Microbiology, 2025. 15: p. 1691215. 在全球公共卫生面临的诸多挑战中，多重耐药（MDR）肺炎克雷伯菌（Klebsiella pneumoniae，KP）的蔓延无疑是最为紧迫的危机之一。作为医院内感染和社区获得性感染的主要病原体，KP不仅引起肺炎、尿路感染和菌血症，其耐药性的进化速度更是令人咋舌。特别是碳青霉烯耐药肺炎克雷伯菌（CRKP）的出现，使得传统的抗生素防线岌岌可危。本文基于2025年Ding等人发表的最新综述，深入剖析了KP耐药的六大核心机制——从药物靶点突变到异质性耐药的复杂网络，并全面评估了以噬菌体为核心的联合疗法（Phage-based combination therapies）的最新进展。无论是噬菌体与抗生素的协同增效，还是与抗菌肽、纳米载体的跨界融合，这些新兴策略正为我们描绘出一幅对抗超级细菌的全新蓝图。 01 危机前夜——全球流行病学与治疗困境肺炎克雷伯菌是一种革兰氏阴性机会性病原体，广泛存在于环境及人体胃肠道中。然而，其一旦进入血液循环，引发的菌血症致死率可高达20%至33%。流行病学数据显示，KP的威胁已呈现全球化与“全健康”（One Health）的特征：亚洲热点：在印度、巴基斯坦和越南等地，MDR与高毒力菌株共存的现象日益普遍。印度99.4%的分离株携带 blaOXA 变体。人畜共患：埃及的马源性KP表现出100%的头孢噻肟耐药性，且牛源性MDRKP对β-内酰胺类药物完全耐药，证实了家畜作为耐药基因库的危险性。全球蔓延：2023年欧洲抗微生物药物耐药性监测网络（EARS-Net）报告显示，CRKP菌血症发病率较2019年激增57.5%。中国CHINET监测网络同期数据显示，2023年CRKP检出率达10.8%，较十年前增长了1.6倍。面对如此严峻的形势，世界卫生组织（WHO）已将CRKP列为2024年“对人类健康构成最大威胁的耐药细菌”清单中的关键优先级病原体。传统疗法如多粘菌素、替加环素及新型酶抑制剂复方制剂（如头孢他啶/阿维巴坦，CAZ/AVI）虽仍是主力，但毒副作用大、疗效有限及耐药性的再次进化，迫使科学界寻找新的出路。 02 分子迷宫——肺炎克雷伯菌的多维耐药机制 KP之所以成为难以攻克的“超级细菌”，归因于其构建的一套多维、协同的分子防御网络。这不仅是单一基因的突变，更是涉及酶修饰、物理屏障、外排泵及群体感应的系统性工程。图1 抗菌药物耐药机制概述：(1) 药物靶点改变（β-内酰胺类、四环素类、氨基糖苷类、喹诺酮类、多粘菌素类）；(2) 酶修饰（β-内酰胺类、氨基糖苷类、氯霉素类、大环内酯类）；(3) 抗菌药物渗透屏障（β-内酰胺类）；(4) 主动外排系统（β-内酰胺类、喹诺酮类、四环素类、大环内酯类、氯霉素类、氨基糖苷类、染料类、表面活性剂类）；(5) 生物膜形成（β-内酰胺类、氨基糖苷类）。 1. 药物靶点的狡猾变异 (Alterations of Drug Target Sites) 细菌通过改变抗生素攻击的目标结构，使其“无的放矢”。青霉素结合蛋白（PBPs）的突变：PBPs是β-内酰胺类药物的靶点。研究发现，PBP3（由 ftsI 基因编码）的突变是导致CAZ/AVI耐药的关键。例如，L367Q突变或T-1-P-Y四氨基酸插入，均能显著降低抗生素与靶点的亲和力，从而逃避药物杀伤。核糖体的甲基化与突变：针对替加环素，KP通过S10蛋白（如Val57Leu突变）改变核糖体构象，阻碍药物结合。针对氨基苷类，ArmA甲基化酶可对16S rRNA的G1405位点进行甲基化，通过静电排斥和空间位阻效应，使细菌对除链霉素外的大多数氨基苷类药物产生广谱耐药。 DNA旋转酶与拓扑异构酶的重构：喹诺酮类药物依赖抑制DNA旋转酶（GyrA/GyrB）和拓扑异构酶IV（ParC/ParE）来阻断细菌DNA复制。KP通过在喹诺酮耐药决定区（QRDRs）发生关键突变（如GyrA-Ser83Ile），大幅降低药物结合力。虽然质粒介导的耐药基因（如 qnr）存在，但QRDR突变仍是高水平耐药的主导因素。脂质A（Lipid A）的修饰：作为多粘菌素的靶点，脂质A的电荷状态至关重要。KP利用双组分系统（如CrrA/B, PmrA/B, PhoP/Q）调控基因，通过添加L-Ara4N或pEtN基团，增加细胞膜正电荷，从而“同性相斥”排斥阳离子多粘菌素。 2. 酶介导的药物灭活 (Modified Enzyme-Mediated Inactivation) 这是KP最令人头疼的耐药手段。细菌产生各种酶来水解或修饰抗生素，使其在到达靶点前失效。 β-内酰胺酶：从经典的ESBLs（如CTX-M-15）到碳青霉烯酶（如KPC-2, NDM-1, OXA-48），这些酶能高效水解青霉素、头孢菌素甚至碳青霉烯类药物。氨基苷类修饰酶（AMEs）：通过乙酰化、磷酸化或核苷酸化修饰，使氨基苷类抗生素失去活性。 3. 铜墙铁壁般的渗透屏障 (Permeability Barriers) 荚膜多糖（CPS）：KP厚实的荚膜不仅是物理屏障，还能通过与LPS O-抗原的相互作用增强滞留，阻挡药物渗透。研究表明，抑制CPS合成（如使用异阿魏酸）可显著增加细菌对补体杀伤的敏感性。孔蛋白（Porins）的缺失：OmpK35和OmpK36是抗生素进入菌体的主要通道。KP通过突变或下调这些孔蛋白，直接切断药物的“补给线”，这是导致CAZ/AVI耐药的重要协同机制。 4. 主动外排系统 (Active Efflux Systems) KP配备了高效的“垃圾处理站”——外排泵，将进入菌体的药物泵出。其中，RND家族的AcrAB-TolC和OqxAB系统最为关键，它们具有极宽的底物特异性，能同时排出β-内酰胺类、喹诺酮类等多种药物，是多重耐药的重要推手。 5. 群体防御：生物被膜与持留菌 (Biofilm, Persisters & QS) 当KP形成生物被膜（Biofilm）时，其耐药性可比浮游状态提高1000倍。 EPS屏障：胞外聚合物（EPS）形成致密网状结构，物理阻隔大分子药物，并通过电荷吸附阻挡氨基苷类药物。持留菌（Persisters）：膜内存在处于代谢休眠状态的持留菌，它们不生长、不分裂，因此对靶向代谢过程的抗生素天然免疫，是慢性感染复发的根源。群体感应（QS）：细菌通过QS系统（如AI-2信号分子）“交流”情报，协调生物被膜的形成。抑制QS信号（如干扰LuxS酶）可导致生物被膜结构松散，成为潜在的治疗突破口。 6. 隐形杀手：异质性耐药 (Heteroresistance) 异质性耐药是指在主要敏感的菌群中，隐藏着极少数高耐药亚群。这种现象在常规药敏试验中常被漏检，却能在抗生素治疗压力下迅速扩增，导致治疗失败。例如，磷酸依特米星/他唑巴坦的异质性耐药与β-内酰胺酶基因拷贝数扩增密切相关。 03 破局之道——基于噬菌体的联合疗法面对抗生素的乏力，噬菌体（Bacteriophage）——这一细菌的天敌，正被重新武装。噬菌体疗法不仅具有高度的特异性，还能通过裂解机制迅速杀死细菌。然而，单一噬菌体疗法面临细菌迅速产生抗性、宿主范围窄等局限。因此，“联合疗法”成为了研究的核心。图2 基于噬菌体的肺炎克雷伯菌感染联合治疗方案 1. 噬菌体与抗生素的协同 (Phage-Antibiotic Synergy, PAS) 这并非简单的叠加，而是深层的生物学互补：机制互补：抗生素（如多粘菌素）破坏外膜，为噬菌体吸附开路；噬菌体裂解生物被膜，暴露深层细菌给抗生素。进化权衡（Fitness Trade-off）：这是最精彩的博弈。例如，KP为抵抗噬菌体H5，可能会突变 wcaJ 基因（负责荚膜合成）。这种突变虽然挡住了噬菌体，却导致荚膜缺失，使细菌对头孢他啶的敏感性增加了32倍。即“由于防备了噬菌体，却在抗生素面前裸露了软肋”。临床实证：多项研究表明，噬菌体与头孢他啶/阿维巴坦、美罗培南等联用，能有效清除XDR菌株。 2. 噬菌体鸡尾酒疗法 (Phage Cocktail) 通过混合多种针对不同受体的噬菌体，构建“鸡尾酒”制剂，可以：扩大宿主谱：覆盖更多样的KP菌株。封锁逃逸路径：细菌很难同时对多种攻击机制不同的噬菌体产生突变。案例：NIH的研究显示，使用噬菌体组合成功抑制了ST258型CRKP的传播；Le等人使用三噬菌体鸡尾酒静脉注射，成功治愈了肾移植患者复发性ESBL-KP尿路感染。 3. 噬菌体与抗菌肽 (Phage-AMPs) 抗菌肽（AMPs）如ε-聚赖氨酸（ε-PL）具有阳离子特性，能与带负电的噬菌体尾部蛋白相互作用，增强噬菌体对细菌膜的穿透力，同时破坏细菌膜电位，加速噬菌体DNA注入，实现“1+1>2”的杀菌效果。 4. 跨界融合：纳米载体、光动力与群体感应抑制剂纳米载体：利用脂质体或磁性纳米材料封装噬菌体，解决其稳定性差的问题，并实现靶向递送。光动力疗法（PDT）：噬菌体携带光敏剂，裂解细菌后释放光敏剂，在光照下产生活性氧（ROS），进一步清除残留细菌和生物被膜。群体感应抑制剂（QSIs）：如肉桂醛（Cinnamaldehyde）可下调QS基因，破坏细菌的通讯网络，使原本对噬菌体耐药的菌株重新变得敏感。 04 临床转化的挑战与未来展望尽管前景广阔，但从实验室走向病床仍有鸿沟：监管与标准化：目前缺乏针对“活体生物药+化学药”的统一审批标准。噬菌体作为生物制剂，其批次间的效价波动（可达10³ PFU/mL）给质量控制带来巨大挑战。免疫反应：人体免疫系统可能会产生抗噬菌体抗体，加速清除噬菌体，削弱疗效。安全性数据：缺乏大规模随机对照试验（RCTs）来验证其药代动力学和毒理学特征。未来方向：分子层面：利用冷冻电镜解析噬菌体-宿主相互作用。基因工程：利用CRISPR-Cas系统改造噬菌体，使其携带能破坏耐药基因的“载荷”。临床试验：亟需开展针对MDRKP感染人群的大规模临床试验，以确立最佳给药时机和剂量。 05 结语对抗多重耐药肺炎克雷伯菌是一场与时间的赛跑。随着我们对其耐药机制理解的加深，基于噬菌体的多维度联合疗法正从理论走向实践。这不仅是技术的革新，更是治疗理念的转变——从单一的化学对抗，走向生物协同的精准打击。在后抗生素时代，这种融合策略或许是我们手中最锋利的武器。 06 附录：文中表格表1：肺炎克雷伯菌中由β-内酰胺酶和氨基苷类修饰酶（AMEs）介导的耐药机制汇总酶大类酶亚型代表性酶耐药机制描述 β-内酰胺酶超广谱β-内酰胺酶 (ESBLs) CTX-M-15, SHV-12, TEM-1 水解β-内酰胺类抗生素（青霉素类、头孢菌素类和单环β-内酰胺类）。肺炎克雷伯菌碳青霉烯酶 (KPC) KPC-2, KPC-3 对碳青霉烯类（亚胺培南、美罗培南）、青霉素类（氨苄西林）和头孢菌素类具有水解活性。 AmpC β-内酰胺酶 CMY-2, DHA-1 水解β-内酰胺类抗生素（主要是头孢菌素类和青霉素类）。金属β-内酰胺酶 (MBLs) NDM-1, VIM-2, IMP-1 活性位点存在锌离子，催化β-内酰胺环水解，导致碳青霉烯类、头孢菌素类和单环β-内酰胺类失活。 OXA型碳青霉烯酶 OXA-48 水解碳青霉烯类抗生素（美罗培南和亚胺培南）、广谱头孢菌素类，甚至非β-内酰胺类抗生素。 AMEs 乙酰转移酶 (AACs) AAC(6')-Ib 乙酰化修饰氨基苷类抗生素（妥布霉素、阿米卡星和奈替米星）的6'-羟基。磷酸转移酶 (APHs) APH(3')-Ib 磷酸化修饰氨基苷类抗生素（卡那霉素和新霉素）的3'-羟基位置。核苷酰转移酶 (ANT) ANT(2")-Ia 对氨基苷类抗生素（庆大霉素和妥布霉素）进行酶促磷酸化或腺苷酰化修饰。表2：RND家族内的耐药基因/系统及其对应的抗微生物药物基因/系统名称影响的抗微生物药物 AcrAB-TolC β-内酰胺类, 喹诺酮类, 四环素类, 大环内酯类, 氯霉素, 氨基苷类, 染料 (吖啶黄, 溴化乙锭, 罗丹明6G), 表面活性剂 (SDS, TPP Cl), 胆酸钠 OqxAB β-内酰胺类, 氨基苷类, 四环素类, 氟喹诺酮类, 氯霉素, 硝基呋喃类, 染料 (吖啶黄, 溴化乙锭, 罗丹明6G), 表面活性剂 (SDS, TPP Cl), 胆酸钠 tmexCD1-toprJ1 四环素类, 喹诺酮类, 头孢菌素类, 氨基苷类 kexEF, FefAB β-内酰胺类, 大环内酯类, 四环素类, 喹诺酮类, 染料 (吖啶黄, 溴化乙锭, 罗丹明6G), 表面活性剂 (SDS, TPP Cl), 胆酸钠 kexC β-内酰胺类, 大环内酯类, 染料 (吖啶黄, 溴化乙锭) kexD 大环内酯类, 染料 (吖啶黄, 溴化乙锭) kexVWX 染料 (吖啶黄, 溴化乙锭), 表面活性剂 (SDS) kexJK 表面活性剂 (SDS) kexSR, kexTU 染料 (吖啶黄, 溴化乙锭) 表3：针对肺炎克雷伯菌（KP）的噬菌体疗法临床研究摘要 (2019-2024) 年份感染类型菌株耐药性治疗策略抗生素疗程给药途径结果 2023 肺部感染 MDRKP F KP_GWPB35 (单药) → F KP_CWPB35 + F KP_CWPA139 (鸡尾酒) 联合抗生素两个疗程雾化吸入症状改善，但未完全清除病原体，出现了毒力降低的噬菌体耐药菌株。 2023 尿路感染 (UTIs) ESBL Metamorpho + Mineola + pKP20 (鸡尾酒) NA 4周静脉注射 (IV) ESBL产酶菌株被完全清除，1年内无复发。 2022 假体关节感染 (PJI) ESBL KP1(2天)+KP2(2天)+KP1+KP2 (鸡尾酒) 厄他培南 6天关节内注射(IA, 4天) + 静脉注射(IV, 2天) 症状改善，14个月无复发，关节功能恢复。 2021 尿路感染 (UTIs) NA 定制噬菌体, Intesti噬菌体, SES噬菌体含甲硝唑、咪康唑、积雪草提取物、多粘菌素B和新霉素的阴道栓剂三个疗程 (20天+15天+1月) 口服 + 阴道栓剂病原体未被清除。 2021 骨折相关感染 (FRI) PDR-KP (泛耐药) 预适应噬菌体 M1 美罗培南和多粘菌素，随后CAZ/AVI 5天噬菌体治疗 + 3个月抗生素治疗局部 + 静脉注射感染得到控制，3年无复发，患者恢复行走能力。 2021 复发性UTIs ESBL 未指明噬菌体种类美罗培南 29天直肠给药最终需进行肾切除术以彻底治疗，噬菌体疗法的贡献不明确。 2020 肺部感染 PDR-KP 噬菌体 KPV811 + KPV15 美罗培南 4天吸入 + 鼻胃管给药支气管肺泡灌洗液中未检测到KP，但粪便样本中分离出敏感菌株。 2020 尿路感染 (UTIs) XDR-KP (广泛耐药) SZ-1等5种 (鸡尾酒) + KP165等5种 (鸡尾酒) + KP152等6种 (鸡尾酒) 第三疗程联合磺胺甲恶唑 (SMZ-TMP) 5天 (三个疗程) 膀胱冲洗前两个疗程出现噬菌体耐药菌，第三疗程后彻底清除病原体，6个月无复发。 2020 MDR细菌肠道定植 MDRKP 定制裂解噬菌体 (vB_KPnM_GF) CAZ-AVI 21天口服 + 直肠内给药肠道定植细菌被完全清除。

微生物疗法

100 项与替加环素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01079	替加环素	J01AA12	DB00560

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
腹腔脓肿	日本	Pfizer Japan, Inc.	2012-09-28
胆囊炎	日本	Pfizer Japan, Inc.	2012-09-28
腹膜炎	日本	Pfizer Japan, Inc.	2012-09-28
脓皮症	日本	Pfizer Japan, Inc.	2012-09-28
继发感染	日本	Pfizer Japan, Inc.	2012-09-28
细菌感染	中国	Ayerst-Wyeth Pharmaceuticals, Inc.	2010-11-10
腹腔感染	中国	Ayerst-Wyeth Pharmaceuticals, Inc.	2010-11-10
细菌性肺炎	中国	Ayerst-Wyeth Pharmaceuticals, Inc.	2010-11-10
社区获得性细菌性肺炎	美国	PF Prism CV	2009-03-20
耐甲氧西林金黄色葡萄球菌感染	澳大利亚	Pfizer Australia Pty Ltd.	2008-05-14
复杂的皮肤和软组织感染	欧盟	Pfizer Europe MA EEIG	2006-04-24
复杂的皮肤和软组织感染	冰岛	Pfizer Europe MA EEIG	2006-04-24
复杂的皮肤和软组织感染	列支敦士登	Pfizer Europe MA EEIG	2006-04-24
复杂的皮肤和软组织感染	挪威	Pfizer Europe MA EEIG	2006-04-24
复杂腹腔感染	美国	PF Prism CV	2005-06-15
复杂皮肤和皮肤结构感染	美国	PF Prism CV	2005-06-15

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
皮肤和皮肤结构感染	临床3期	-	Wyeth AB	2011-08-01
糖尿病足感染	临床3期	美国	Wyeth AB	2007-01-01
糖尿病足感染	临床3期	中国	Wyeth AB	2007-01-01
糖尿病足感染	临床3期	阿根廷	Wyeth AB	2007-01-01
糖尿病足感染	临床3期	澳大利亚	Wyeth AB	2007-01-01
糖尿病足感染	临床3期	奥地利	Wyeth AB	2007-01-01
糖尿病足感染	临床3期	比利时	Wyeth AB	2007-01-01
糖尿病足感染	临床3期	巴西	Wyeth AB	2007-01-01
糖尿病足感染	临床3期	加拿大	Wyeth AB	2007-01-01
糖尿病足感染	临床3期	智利	Wyeth AB	2007-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02573064 (Pubmed \| Clin Microbiol Infect)	N/A	碳青霉烯类耐药鲍曼不动杆菌感染	118	Monotherapy with colistin	淵齋蓋齋膚餘鏇鑰遞範(範鏇鏇艱繭齋鏇網淵艱) = 選鬱鏇蓋壓築鬱簾構艱糧願衊窪憲鬱餘淵蓋窪 (醖鬱顧憲醖齋選築糧顧 )	不佳	2018-06-01
				Combined therapy with colistin and tigecycline	淵齋蓋齋膚餘鏇鑰遞範(範鏇鏇艱繭齋鏇網淵艱) = 構餘鬱簾鹽範糧夢鹽製糧願衊窪憲鬱餘淵蓋窪 (醖鬱顧憲醖齋選築糧顧 )
NCT01721408 (CTgov)	临床4期	复杂腹腔感染	470	Tigecycline (Tigecycline 50mg)	淵壓簾蓋蓋餘願遞築網 = 夢鏇鑰願鹽憲蓋顧積鬱壓鏇糧餘廠壓簾網積齋 (餘築醖願顧顧繭壓積鏇, 構壓膚窪壓製範遞餘醖 ~ 廠製醖衊鹽齋夢醖醖壓) 更多	-	2018-04-09
				Imipenem+Cilastatin (Imipenem/Cilastatin)	淵壓簾蓋蓋餘願遞築網 = 觸夢構壓積廠範網鏇範壓鏇糧餘廠壓簾網積齋 (餘築醖願顧顧繭壓積鏇, 齋觸鹽襯壓繭衊簾夢願 ~ 繭遞蓋繭憲壓範窪淵遞) 更多
NCT01721408 (Pubmed \| Ther Clin Risk Manag)	临床4期	复杂腹腔感染	470	Tigecycline	積網築繭蓋鬱鑰襯衊餘(網願範齋衊餘鑰淵鹽鑰) = nausea, drug ineffectiveness, postoperative wound infection, vomiting, and pyrexia were the most common adverse events in tigecycline-treated subjects 壓遞製觸壓壓齋憲壓衊 (齋鹽繭觸淵夢獵鏇淵廠 ) 更多	-	2018-01-01
				Imipenem/cilastatin
EHA2017	N/A	血液肿瘤 \| 粒细胞减少性发热	109	Tigecycline	窪蓋構鑰餘窪鹽構夢鏇(窪憲獵糧顧築淵糧鹽鑰) = The side-effects were well tolerated. No lethal adverse events were observed. 夢顧憲築醖膚網顧遞簾 (網觸獵構製襯選構襯範 )	积极	2017-05-18
NCT01560143 (CTgov)	临床4期	肥胖	12	Tigecycline	壓構廠膚餘壓醖艱鏇醖(構鏇積積簾網齋衊鹹範) = 鏇淵築鏇鹹鹹蓋壓積顧繭範鏇築選鹽窪觸廠範 (獵願繭顧襯構壓構夢膚, 網餘鏇網齋餘築餘鹹鹹 ~ 築簾築顧糧構繭襯構簾) 更多	-	2016-12-06
NCT00719810 (Pubmed \| Int J Infect Dis)	临床2期	复杂皮肤和皮肤结构感染	150	Delafloxacin 300mg IV every 12h	鬱鑰齋膚壓衊憲醖鏇餘(淵廠遞壓淵範窪製鏇淵) = 願鏇築餘淵蓋鹽糧醖廠淵憲夢蓋選鑰鹽艱顧製 (選壓網願繭醖觸範淵廠 )	-	2015-01-01
				Delafloxacin 450mg IV every 12h	鬱鑰齋膚壓衊憲醖鏇餘(淵廠遞壓淵範窪製鏇淵) = 構網簾膚簾餘範餘遞獵淵憲夢蓋選鑰鹽艱顧製 (選壓網願繭醖觸範淵廠 )
NCT00600600 \| NCT00205816 (Study 310, Pubmed \| J Antimicrob Chemother)	临床2/3期	脓肿分枝杆菌感染	52	Tigecycline-containing regimens	蓋鏇範製餘範餘夢製艱(範鏇獵觸遞網網蓋繭獵) = Adverse events were reported in >90% of cases, the most common being nausea and vomiting 齋簾製糧製衊選衊醖簾 (衊襯鏇鏇糧顧製繭鏇蓋 )	-	2014-07-01
NCT00366249 (Pubmed \| Diagn Microbiol Infect Dis)	临床3期	糖尿病足感染	944	Tigecycline	鹹廠壓願蓋廠蓋鑰製範(獵衊衊鹽積鏇壓糧鏇選) = Nausea and vomiting occurred significantly more often after tigecycline treatment 襯齋膚醖構膚獵鹽願襯 (蓋簾網膚鏇鹹鹽顧範壓 ) 更多	不佳	2014-04-01
				Ertapenem ± vancomycin
NCT01560143 (Pubmed \| J Antimicrob Chemother)	临床4期	肥胖	12	tigecycline (Obese class III adults)	壓鹹構壓蓋積鬱顧憲鑰(願襯膚獵繭顧遞鬱醖壓) = 鑰膚鹽鬱鬱簾顧鬱醖鬱選衊衊繭齋淵艱鑰繭蓋 (網艱鹽製製壓壓鹽淵鬱 ) 更多	-	2014-01-01
				tigecycline (Normal weight adults)	壓鹹構壓蓋積鬱顧憲鑰(願襯膚獵繭顧遞鬱醖壓) = 願願積衊選廠積齋夢艱選衊衊繭齋淵艱鑰繭蓋 (網艱鹽製製壓壓鹽淵鬱 ) 更多
NCT00376324 (Pubmed \| J Clin Pharmacol)	临床1期	-	-	Tigecycline	膚襯鏇鹽窪繭積襯鏇願(製餘窪蓋夢膚網壓衊積) = 構艱鏇觸餘憲廠廠觸繭顧構衊願觸範艱顧遞壓 (醖範繭繭願艱廠膚簾蓋 )	-	2014-01-01